Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Ribavirin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 4/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 1.00 |
| ▸ | TSHR | P16473 | 2/20 | 1.00 |
| ▸ | ADORA1 | P30542 | 2/20 | 1.00 |
| ▸ | THPO | P40225 | 2/20 | 1.00 |
| ▸ | PMP22 | Q01453 | 2/20 | 1.00 |
| ▸ | GLA | P06280 | 1/20 | 1.00 |
| ▸ | EIF4E | P06730 | 1/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 1/20 | 1.00 |
| ▸ | TOP1 | P11387 | 1/20 | 1.00 |
| ▸ | PNP | P00491 | 4/20 | 0.76 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.56 |
| ▸ | HTT | P42858 | 2/20 | 0.56 |
| ▸ | BLM | P54132 | 2/20 | 0.56 |
| ▸ | TP53 | P04637 | 2/20 | 0.56 |
| ▸ | MAPT | P10636 | 2/20 | 0.56 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.56 |
| ▸ | GAA | P10253 | 1/20 | 0.56 |
| ▸ | HTR2C | P28335 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ribavirin SCHEMBL1981630 | 1.00 | LMNA (1.00) | LMNASMN1; SMN2ALDH1A1TSHRADORA1 | |
| Ribavirin SCHEMBL326516 | 1.00 | LMNA (1.00) | LMNASMN1; SMN2ALDH1A1TSHRADORA1 | |
| Ribavirin SCHEMBL427229 | 1.00 | LMNA (1.00) | LMNASMN1; SMN2ALDH1A1TSHRADORA1 | |
| Ribavirin SCHEMBL14379766 | 1.00 | LMNA (1.00) | LMNASMN1; SMN2ALDH1A1TSHRADORA1 | |
| Ribavirin SCHEMBL12758160 | 1.00 | LMNA (1.00) | LMNASMN1; SMN2ALDH1A1TSHRADORA1 | |
| Ribavirin SCHEMBL18537396 | 1.00 | LMNA (1.00) | LMNASMN1; SMN2ALDH1A1TSHRADORA1 | |
| Ribavirin SCHEMBL3954927 | 1.00 | LMNA (1.00) | LMNASMN1; SMN2ALDH1A1TSHRADORA1 | |
| Ribavirin SCHEMBL21311208 | 1.00 | LMNA (1.00) | LMNASMN1; SMN2ALDH1A1TSHRADORA1 | |
| Ribavirin SCHEMBL20806078 | 1.00 | LMNA (1.00) | LMNASMN1; SMN2ALDH1A1TSHRADORA1 | |
| Ribavirin SCHEMBL379651 | 1.00 | LMNA (1.00) | LMNASMN1; SMN2ALDH1A1TSHRADORA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 628 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2640720-B1 | BIFUNCTIONAL MOLECULES WITH ANTIBODY-RECRUITING AND ENTRY INHIBITORY ACTIVITY AGAINST THE HUMAN IMMUNODEFICIENCY VIRUS | YALE UNIV INC (US) | 2018-10-17 | — | — | EP | claimed |
| US-9745334-B2 | Cytotoxic-drug delivering molecules targeting HIV (CDM-Hs), cytotoxic activity against the human immunodeficiency virus and methods of use | YALE UNIVERSITY (US) | 2017-08-29 | — | — | US | claimed |
| US-9562038-B2 | Bifunctional molecules with antibody-recruiting and entry inhibitory activity against the human immunodeficiency virus | YALE UNIVERSITY (US) | 2017-02-07 | — | — | US | claimed |
| US-20160082102-A1 | BIFUNCTIONAL MOLECULES WITH ANTIBODY-RECRUITING AND ENTRY INHIBITORY ACTIVITY AGAINST THE HUMAN IMMUNODEFICIENCY VIRUS | UNIV YALE (US) | 2016-03-24 | — | — | US | claimed |
| US-20150087609-A1 | CYTOTOXIC-DRUG DELIVERING MOLECULES TARGETING HIV (CDM-HS), CYTOTOXIC ACTIVITY AGAINST THE HUMAN IMMUNODEFICIENCY VIRUS AND METHODS OF USE | YALE UNIVERSITY | 2015-03-26 | — | — | US | claimed |
| EP-2841107-A1 | CYTOTOXIC-DRUG DELIVERING MOLECULES TARGETING HIV (CDM-HS), CYTOTOXIC ACTIVITY AGAINST THE HUMAN IMMUNODEFICIENCY VIRUS AND METHODS OF USE | Yale University (US) | 2015-03-04 | — | — | EP | claimed |
| WO-2013162757-A1 | CYTOTOXIC-DRUG DELIVERING MOLECULES TARGETING HIV (CDM-HS), CYTOTOXIC ACTIVITY AGAINST THE HUMAN IMMUNODEFICIENCY VIRUS AND METHODS OF USE | YALE UNIVERSITY (US) | 2013-10-31 | — | — | WO | claimed |
| EP-2640720-A2 | BIFUNCTIONAL MOLECULES WITH ANTIBODY-RECRUITING AND ENTRY INHIBITORY ACTIVITY AGAINST THE HUMAN IMMUNODEFICIENCY VIRUS | Yale University, Inc. (US) | 2013-09-25 | — | — | EP | claimed |
| US-20130245040-A1 | BIFUNCTIONAL MOLECULES WITH ANTIBODY-RECRUITING AND ENTRY INHIBITORY ACTIVITY AGAINST THE HUMAN IMMUNODEFICIENCY VIRUS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2013-09-19 | — | — | US | claimed |
| WO-2012068366-A9 | BIFUNCTIONAL MOLECULES WITH ANTIBODY-RECRUITING AND ENTRY INHIBITORY ACTIVITY AGAINST THE HUMAN IMMUNODEFICIENCY VIRUS | YALE UNIVERSITY (US) | 2013-07-18 | — | — | WO | claimed |
| US-20120269766-A1 | BIFUNCTIONAL MOLECULES WITH ANTIBODY-RECRUITING AND ENTRY INHIBITORY ACTIVITY AGAINST THE HUMAN IMMUNODEFICIENCY VIRUS | YALE UNIVERSITY (US) | 2012-10-25 | — | — | US | claimed |
| WO-2012068366-A2 | BIFUNCTIONAL MOLECULES WITH ANTIBODY-RECRUITING AND ENTRY INHIBITORY ACTIVITY AGAINST THE HUMAN IMMUNODEFICIENCY VIRUS | YALE UNIVERSITY (US) | 2012-05-24 | — | — | WO | claimed |
| WO-2012051492-A2 | COMPOUNDS AND METHODS FOR INHIBITING HIV LATENCY | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 2012-04-19 | — | — | WO | claimed |
| WO-2011046946-A2 | BIFUNCTIONAL MOLECULES WITH ANTIBODY-RECRUITING AND ENTRY INHIBITORY ACTIVITY AGAINST THE HUMAN IMMUNODEFICIENCY VIRUS | YALE UNIVERSITY (US) | 2011-04-21 | — | — | WO | claimed |
| CN-101317577-A | Medicament for preventing and controlling plant virus disease | TAI AN XIANHE AGRICULTURAL TEC (CN) | 2008-12-10 | — | — | CN | claimed |
| EP-1910337-A2 | HETEROARYL DERIVATIVES FOR TREATING VIRUSES | GENELABS TECHNOLOGIES, INC. (US) | 2008-04-16 | — | — | EP | claimed |
| WO-2007019397-A2 | 6-MEMBERED ARYL AND HETEROARYL DERIVATIVES FOR THE TREATMENT OF HEPATITIS C VIRUS | GENELABS TECHNOLOGIES, INC. (US) | 2007-02-15 | — | — | WO | claimed |
| WO-2006138744-A2 | HETEROARYL DERIVATIVES FOR TREATING VIRUSES | GENELABS TECHNOLOGIES, INC. (US) | 2006-12-28 | — | — | WO | claimed |
| EP-0617968-B1 | HIV protease inhibitors in pharmaceutical combinations for the treatment of AIDS | MERCK & CO INC (US) | 2003-01-08 | — | — | EP | claimed |
| US-11858917-B2 | Bifunctional molecules with antibody-recruiting and entry inhibitory activity against the human immunodeficiency virus | YALE UNIVERSITY (US) | 2024-01-02 | — | — | US | disclosed |
| US-20230295277-A1 | UNIVERSAL CAR-NK CELL TARGETING VARIOUS EPITOPES OF HIV-1 GP160 | UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 2023-09-21 | — | — | US | disclosed |
| US-11730748-B2 | Cyclic phosphate substituted nucleoside derivatives for the treatment of liver diseases | MSD INTERNATIONAL GMBH (CH) | 2023-08-22 | — | — | US | disclosed |
| EP-3831839-B1 | C-3 AND C-17 MODIFIED TRITERPENOIDS AS HIV-1 INHIBITORS | VIIV HEALTHCARE UK NO 5 LTD (GB) | 2023-07-26 | — | — | EP | disclosed |
| EP-4178626-A2 | UNIVERSAL CAR-NK CELL TARGETING VARIOUS EPITOPES OF HIV-1 GP160 | University of Southern California (US) | 2023-05-17 | — | — | EP | disclosed |
| EP-2909209-B1 | 2'-CYANO SUBSTITUTED NUCLEOSIDE DERIVATIVES AND METHODS OF USE THEREOF FOR TREATMENT OF VIRAL DISEASES | MERCK SHARP & DOHME LLC (US) | 2022-08-03 | — | — | EP | disclosed |
| EP-4005600-A1 | CYTOTOXIC-DRUG DELIVERING MOLECULES TARGETING HIV (CDM-HS), CYTOTOXIC ACTIVITY AGAINST THE HUMAN IMMUNODEFICIENCY VIRUS AND METHODS OF USE | Yale University (US) | 2022-06-01 | — | — | EP | disclosed |
| WO-2022015754-A2 | UNIVERSAL CAR-NK CELL TARGETING VARIOUS EPITOPES OF HIV-1 GP160 | UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 2022-01-20 | — | — | WO | disclosed |
| EP-2841107-B1 | CYTOTOXIC-DRUG DELIVERING MOLECULES TARGETING HIV (CDM-HS), CYTOTOXIC ACTIVITY AGAINST THE HUMAN IMMUNODEFICIENCY VIRUS AND METHODS OF USE | UNIV YALE (US) | 2021-11-03 | — | — | EP | disclosed |
| US-11136316-B2 | Bifunctional molecules with antibody-recruiting and entry inhibitory activity against the Human Immunodeficiency Virus | YALE UNIVERSITY (US) | 2021-10-05 | — | — | US | disclosed |
| US-20210205339-A1 | CYCLIC PHOSPHATE SUBSTITUTED NUCLEOSIDE DERIVATIVES FOR THE TREATMENT OF LIVER DISEASES | MSD INTERNATIONAL GMBH (CH) | 2021-07-08 | — | — | US | disclosed |
| US-10899788-B2 | Cyclic phosphate substituted nucleoside compounds and methods of use thereof for the treatment of viral diseases | MERCK SHARP & DOHME CORP. (US) | 2021-01-26 | — | — | US | disclosed |
| EP-3411381-B1 | C-3 AND C-17 MODIFIED TRITERPENOIDS AS HIV-1 INHIBITORS | VIIV HEALTHCARE UK NO 5 LTD (GB) | 2021-01-20 | — | — | EP | disclosed |
| US-10881700-B1 | Compositions including extracts of gray mangrove leaves and methods of treatment using such compositions in treatment of viral infections | KING ABDULLAH UNIVERSITY OF SCIENCE AND TECHNOLOGY (SA) | 2021-01-05 | — | — | US | disclosed |
| US-20200392121-A1 | BIFUNCTIONAL MOLECULES WITH ANTIBODY-RECRUITING AND ENTRY INHIBITORY ACTIVITY AGAINST THE HUMAN IMMUNODEFICIENCY VIRUS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2020-12-17 | — | — | US | disclosed |
| EP-3750910-A1 | TRITERPENOIDS WITH HIV MATURATION INHIBITORY ACTIVITY | VIIV Healthcare UK(No.4) Limited (GB) | 2020-12-16 | — | — | EP | disclosed |
| EP-3478662-B1 | AZADECALIN DERIVATIVES AS INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | VIIV HEALTHCARE UK (NO5) LTD (GB) | 2020-09-16 | — | — | EP | disclosed |
| US-10738062-B2 | Chromane-substituted tetracyclic compounds and uses thereof for the treatment of viral diseases | MERCK SHARP & DOHME CORP. (US) | 2020-08-11 | — | — | US | disclosed |
| EP-3129392-B1 | TRITERPENOIDS WITH HIV MATURATION INHIBITORY ACTIVITY, SUBSTITUTED IN POSITION 3 BY A NON-AROMATIC RING CARRYING A HALOALKYL SUBSTITUENT | VIIV HEALTHCARE UK NO 4 LTD (GB) | 2020-08-05 | — | — | EP | disclosed |
| US-10703743-B2 | Bifunctional molecules with antibody-recruiting and entry inhibitory activity against the human immunodeficiency virus | YALE UNIVERSITY (US) | 2020-07-07 | — | — | US | disclosed |
| US-20200190131-A1 | INCLUSION COMPLEXES OF AN HCV NS5B INHIBITOR AND USES THEREOF | MERCK SHARP & DOHME CORP. (US) | 2020-06-18 | — | — | US | disclosed |
| US-20200179428-A1 | CYCLIC PHOSPHATE SUBSTITUTED NUCLEOSIDE DERIVATIVES AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES | MERCK SHARP & DOHME CORP. (US) | 2020-06-11 | — | — | US | disclosed |
| EP-2919792-B1 | 2 -ALKYNYL SUBSTITUTED NUCLEOSIDE DERIVATIVES FOR TREATING VIRAL DISEASES | MERCK SHARP & DOHME (US) | 2020-05-20 | — | — | EP | disclosed |
| EP-3286166-B1 | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | VIIV HEALTHCARE UK NO 5 LTD (GB) | 2020-05-13 | — | — | EP | disclosed |
| US-10646494-B2 | Heterocycle-substituted tetracyclic compounds and methods of use thereof for the treatment of viral diseases | MERCK SHARP & DOHME CORP. (US) | 2020-05-12 | — | — | US | disclosed |
| EP-3083634-B1 | FUSED TETRACYCLIC HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES | MERCK SHARP & DOHME (US) | 2019-10-23 | — | — | EP | disclosed |
| EP-3541825-A1 | CYCLIC PHOSPHATE SUBSTITUTED NUCLEOSIDE DERIVATIVES FOR THE TREATMENT OF LIVER DISEASES | Idenix Pharmaceuticals LLC. (US) | 2019-09-25 | — | — | EP | disclosed |
| EP-3334723-B1 | 5-(N-[6,5]-FUSED BICYCLIC ARYL TETRAHYDROISOQUINOLIN-6-YL) PYRIDIN-3-YL ACETIC ACID DERIVATIVES AS INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | VIIV HEALTHCARE UK NO 5 LTD (GB) | 2019-09-18 | — | — | EP | disclosed |
| EP-2945952-B1 | HETEROCYCLE-SUBSTITUED TETRACYCLIC COMPOUNDS AND METHODS OF USE THEREOF FOR TREATMENT OF VIRAL DISEASES | MERCK SHARP & DOHME (US) | 2019-08-28 | — | — | EP | disclosed |
| US-20190233463-A1 | CYCLIC PHOSPHATE SUBSTITUTED NUCLEOSIDE COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES | MERCK SHARP & DOHME CORP. (US) | 2019-08-01 | — | — | US | disclosed |
| CN-106491583-B | Application of the cirsimaritin in preparation antiviral drugs | 新疆维吾尔自治区药物研究所 | 2019-07-16 | — | — | CN | disclosed |
| US-20190192548-A1 | USE OF CYCLIC PHOSPHATE SUBSTITUTED NUCLEOSIDE DERIVATIVESFOR THE TREATMENT OF VIRAL DISEASES | MERCK SHARP & DOHME CORP. (US) | 2019-06-27 | — | — | US | disclosed |
| EP-3500578-A1 | HETEROCYCLE-SUBSTITUTED TETRACYCLIC COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES | Merck Sharp & Dohme Corp. (US) | 2019-06-26 | — | — | EP | disclosed |
| EP-3500579-A1 | CHROMANE-SUBSTITUTED TETRACYCLIC COMPOUNDS AND USES THEREOF FOR THE TREATMENT OF VIRAL DISEASES | Merck Sharp & Dohme Corp. (US) | 2019-06-26 | — | — | EP | disclosed |
| US-20190185486-A1 | CHROMANE-SUBSTITUTED TETRACYCLIC COMPOUNDS AND USES THEREOF FOR THE TREATMENT OF VIRAL DISEASES | MERCK SHARP & DOHME CORP. (US) | 2019-06-20 | — | — | US | disclosed |
| US-20190175602-A1 | HETEROCYCLE-SUBSTITUTED TETRACYCLIC COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES | MERCK SHARP & DOHME CORP. (US) | 2019-06-13 | — | — | US | disclosed |
| EP-3471739-A1 | USE OF CYCLIC PHOSPHATE SUBSTITUTED NUCLEOSIDE DERIVATIVES FOR THE TREATMENT OF VIRAL DISEASES | Merck Sharp & Dohme Corp. (US) | 2019-04-24 | — | — | EP | disclosed |
| EP-3471738-A1 | CYCLIC PHOSPHATE SUBSTITUTED NUCLEOSIDE DERIVATIVES AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES | Merck Sharp & Dohme Corp. (US) | 2019-04-24 | — | — | EP | disclosed |
| EP-3471737-A1 | CYCLIC PHOSPHATE SUBSTITUTED NUCLEOSIDE COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES | Merck Sharp & Dohme Corp. (US) | 2019-04-24 | — | — | EP | disclosed |
| US-10188727-B2 | Bifunctional molecules with antibody-recruiting and entry inhibitory activity against the human immunodeficiency virus | YALE UNIVERSITY (US) | 2019-01-29 | — | — | US | disclosed |
| US-20190002480-A1 | Silane-Containing Heterocyclic Compounds and Methods of Use Thereof for the Treatment of Viral Diseases | MERCK SHARP & DOHME CORP. (US) | 2019-01-03 | — | — | US | disclosed |
| US-20190002447-A1 | BIFUNCTIONAL MOLECULES WITH ANTIBODY-RECRUITING AND ENTRY INHIBITORY ACTIVITY AGAINST THE HUMAN IMMUNODEFICIENCY VIRUS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2019-01-03 | — | — | US | disclosed |
| US-10167298-B2 | Pseudopolymorphs of an HCV NS5A inhibitor and uses thereof | MERCK SHARP & DOHME CORP. (US) | 2019-01-01 | — | — | US | disclosed |
| CN-108938641-A | Application of compound NSC133071 in preparing medicine for treating or preventing influenza virus | 浙江立恩生物科技有限公司 | 2018-12-07 | — | — | CN | disclosed |
| CN-108938627-A | Application of compound NSC343550 in preparation of medicine for treating or preventing influenza virus | 浙江立恩生物科技有限公司 | 2018-12-07 | — | — | CN | disclosed |
| CN-108938639-A | Application of compound NSC305780 in preparation of drugs for treating or preventing influenza viruses | 浙江立恩生物科技有限公司 | 2018-12-07 | — | — | CN | disclosed |
| EP-3393585-A1 | SILANE-CONTAINING HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES | Merck Sharp & Dohme Corp. (US) | 2018-10-31 | — | — | EP | disclosed |
| EP-2640720-B1 | BIFUNCTIONAL MOLECULES WITH ANTIBODY-RECRUITING AND ENTRY INHIBITORY ACTIVITY AGAINST THE HUMAN IMMUNODEFICIENCY VIRUS | YALE UNIV INC (US) | 2018-10-17 | — | — | EP | disclosed |
| EP-2696681-B1 | 2'-SUBSTITUTED NUCLEOSIDE DERIVATIVES AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES | MERCK SHARP & DOHME (US) | 2018-10-03 | — | — | EP | disclosed |
| EP-2697242-B1 | 2'-AZIDO SUBSTITUTED NUCLEOSIDE DERIVATIVES AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES | MERCK SHARP & DOHME (US) | 2018-10-03 | — | — | EP | disclosed |
| EP-2753325-B1 | TETRACYCLIC HETEROCYCLE COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES | MERCK SHARP & DOHME (US) | 2018-09-19 | — | — | EP | disclosed |
| EP-3349741-A1 | COMPOSITION HAVING ANTIVIRAL EFFECT | Medice Arzneimittel Pütter GmbH & Co. KG (DE) | 2018-07-25 | — | — | EP | disclosed |
| US-10030008-B2 | Bifunctional molecules with antibody-recruiting and entry inhibitory activity against the human immunodeficiency virus | YALE UNIVERSITY (US) | 2018-07-24 | — | — | US | disclosed |
| WO-2018091542-A1 | CYCLIC PHOSPHATE SUBSTITUTED NUCLEOSIDE DERIVATIVES FOR THE TREATMENT OF LIVER DISEASES | IDENIX PHARMACEUTICALS LLC (US) | 2018-05-24 | — | — | WO | disclosed |
| CN-107913262-A | Flavaspidic acid AB resisiting influenza virus functions | 中国医学科学院药用植物研究所 | 2018-04-17 | — | — | CN | disclosed |
| EP-2753611-B1 | SUBSTITUTED BENZOFURAN COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES | MERCK SHARP & DOHME (US) | 2018-04-11 | — | — | EP | disclosed |
| EP-2753618-B1 | HETEROCYCLIC-SUBSTITUED BENZOFURAN DERIVATIVES AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES | MERCK SHARP & DOHME (US) | 2018-04-11 | — | — | EP | disclosed |
| EP-2621279-B1 | FUSED TETRACYCLE DERIVATIVES AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES | MERCK SHARP & DOHME (US) | 2018-04-04 | — | — | EP | disclosed |
| EP-2978763-B1 | 2-KETO AMIDE DERIVATIVES AS HIV ATTACHMENT INHIBITORS | VIIV HEALTHCARE UK (NO 5) LTD (GB) | 2018-03-07 | — | — | EP | disclosed |
| CN-107727862-A | A kind of Ribavirin test strip | 北京农学院 | 2018-02-23 | — | — | CN | disclosed |
| WO-2018032467-A1 | CHROMANE-SUBSTITUED TETRACYCLIC COMPOUNDS AND USES THEREOF FOR TREATMENT OF VIRAL DISEASES | MERCK SHARP & DOHME CORP. (US) | 2018-02-22 | — | — | WO | disclosed |
| WO-2018035006-A1 | CHROMANE-SUBSTITUTED TETRACYCLIC COMPOUNDS AND USES THEREOF FOR THE TREATMENT OF VIRAL DISEASES | MERCK SHARP & DOHME CORP. (US) | 2018-02-22 | — | — | WO | disclosed |
| WO-2018035005-A1 | HETEROCYCLE-SUBSTITUTED TETRACYCLIC COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES | MERCK SHARP & DOHME CORP. (US) | 2018-02-22 | — | — | WO | disclosed |
| WO-2018032468-A1 | HETEROCYCLE-SUBSTITUED TETRACYCLIC COMPOUNDS AND METHODS OF USE THEREOF FOR TREATMENT OF VIRAL DISEASES | MERCK SHARP & DOHME CORP. (US) | 2018-02-22 | — | — | WO | disclosed |
| WO-2017223012-A1 | CYCLIC PHOSPHATE SUBSTITUTED NUCLEOSIDE COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES | MERCK SHARP & DOHME CORP. (US) | 2017-12-28 | — | — | WO | disclosed |
| WO-2017223020-A1 | CYCLIC PHOSPHATE SUBSTITUTED NUCLEOSIDE DERIVATIVES AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES | MERCK SHARP & DOHME CORP. (US) | 2017-12-28 | — | — | WO | disclosed |
| WO-2017223024-A1 | USE OF CYCLIC PHOSPHATE SUBSTITUTED NUCLEOSIDE DERIVATIVES FOR THE TREATMENT OF VIRAL DISEASES | MERCK SHARP & DOHME CORP. (US) | 2017-12-28 | — | — | WO | disclosed |
| EP-3010512-B1 | CYCLIC PHOSPHONATE SUBSTITUTED NUCLEOSIDE DERIVATIVES AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES | MERCK SHARP & DOHME (US) | 2017-12-27 | — | — | EP | disclosed |
| US-9828365-B2 | Fused tetracyclic heterocyclic compounds and methods of use thereof for the treatment of viral diseases | MERCK SHARP & DOHME CORP. (US) | 2017-11-28 | — | — | US | disclosed |
| US-9796705-B2 | Fused tricyclic compounds and methods of use thereof for the treatment of viral diseases | MERCK SHARP & DOHME CORP. (US) | 2017-10-24 | — | — | US | disclosed |
| EP-2670765-B1 | C-17 AND C-3 MODIFIED TRITERPENOIDS WITH HIV MATURATION INHIBITORY ACTIVITY | VIIV HEALTHCARE UK (NO 4) LTD (GB) | 2017-10-18 | — | — | EP | disclosed |
| US-9765107-B2 | Cyclic phosphonate substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases | MERCK SHARP & DOHME CORP. (US) | 2017-09-19 | — | — | US | disclosed |
| US-9745334-B2 | Cytotoxic-drug delivering molecules targeting HIV (CDM-Hs), cytotoxic activity against the human immunodeficiency virus and methods of use | YALE UNIVERSITY (US) | 2017-08-29 | — | — | US | disclosed |
| US-9732111-B2 | 2′-alkynyl substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases | MERCK SHARP & DOHME CORP. (US) | 2017-08-15 | — | — | US | disclosed |
| US-20170217940-A1 | FUSED TETRACYCLIC HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES | MERCK SHARP & DOHME CORP. (US) | 2017-08-03 | — | — | US | disclosed |
| EP-2696679-B1 | 2'-CYANO SUBSTITUTED NUCLEOSIDE DERIVATIVES AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES | MERCK SHARP & DOHME (US) | 2017-08-02 | — | — | EP | disclosed |
| EP-2975038-B1 | COMPOSITION AND ANTIVIRAL ACTIVITY OF SUBSTITUTED AZAINDOLEOXOACETIC PIPERAZINE DERIVATIVES | VIIV HEALTHCARE UK(NO 4) LTD (GB) | 2017-07-12 | — | — | EP | disclosed |
| WO-2017112531-A1 | SILANE-CONTAINING HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES | MERCK SHARP & DOHME CORP. (US) | 2017-06-29 | — | — | WO | disclosed |
| EP-2696937-B1 | THIOAMIDE, AMIDOXIME AND AMIDRAZONE DERIVATIVES AS HIV ATTACHMENT INHIBITORS | VIIV HEALTHCARE UK (NO 5) LTD (GB) | 2017-05-17 | — | — | EP | disclosed |
| US-9650360-B2 | Anti-mycobacterial drugs against tuberculosis | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 2017-05-16 | — | — | US | disclosed |
| US-20170096415-A1 | BIFUNCTIONAL MOLECULES WITH ANTIBODY-RECRUITING AND ENTRY INHIBITORY ACTIVITY AGAINST THE HUMAN IMMUNODEFICIENCY VIRUS | UNIV YALE (US) | 2017-04-06 | — | — | US | disclosed |
| WO-2017046312-A1 | COMPOSITION HAVING ANTIVIRAL EFFECT | MEDICE Arzneimittel Pütter GmbH & Co. KG (DE) | 2017-03-23 | — | — | WO | disclosed |
| US-9573939-B2 | Substituted benzofuran compounds and methods of use thereof for the treatment of viral diseases | MERCK SHARP & DOHME CORP. (US) | 2017-02-21 | — | — | US | disclosed |
| US-9562038-B2 | Bifunctional molecules with antibody-recruiting and entry inhibitory activity against the human immunodeficiency virus | YALE UNIVERSITY (US) | 2017-02-07 | — | — | US | disclosed |
| US-9555038-B2 | Heterocycle-substituted tetracyclic compounds and methods of use thereof for the treatment of viral diseases | MERCK SHARP & DOHME CORP. (US) | 2017-01-31 | — | — | US | disclosed |
| US-9549917-B2 | Heterocyclic-substituted benzofuran derivatives and methods of use thereof for the treatment of viral diseases | MERCK SHARP & DOHME CORP. (US) | 2017-01-24 | — | — | US | disclosed |
| US-20170008879-A1 | FUSED TRICYCLIC COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES | MERCK SHARP & DOHME CORP. (US) | 2017-01-12 | — | — | US | disclosed |
| EP-2640729-B1 | INHIBITORS OF HIV REPLICATION | VIIV HEALTHCARE UK LTD (GB) | 2016-12-21 | — | — | EP | disclosed |
| EP-2831056-B1 | NEW ANTI-MYCOBACTERIAL DRUGS AGAINST TUBERCULOSIS | THE UNIV OF GEORGIA RES FOUND INC (US) | 2016-12-14 | — | — | EP | disclosed |
| US-20160355528-A1 | INHIBITORS OF HIV REPLICATION | VIIV HEALTHCARE UK LIMITED (GB) | 2016-12-08 | — | — | US | disclosed |
| EP-2303893-B1 | TRICYCLIC INDOLE DERIVATIVES | MERCK SHARP & DOHME (US) | 2016-12-07 | — | — | EP | disclosed |
| US-9504690-B2 | Tetracyclic xanthene derivatives and methods of use thereof for the treatment of viral diseases | MERCK SHARP & DOHME CORP. (US) | 2016-11-29 | — | — | US | disclosed |
| EP-2895472-B1 | Tricyclic alkene derivatives as HIV attachment inhibitors | VIIV HEALTHCARE UK NO 5 LTD (GB) | 2016-11-23 | — | — | EP | disclosed |
| EP-2895471-B1 | PIPERIDINE AMIDE DERIVATIVES AS HIV ATTACHMENT INHIBITORS | VIIV HEALTHCARE UK NO 5 LTD (GB) | 2016-11-23 | — | — | EP | disclosed |
| EP-2751119-B1 | FUSED BICYCLIC DIAMINE DERIVATIVES AS HIV ATTACHMENT INHIBITORS | VIIV HEALTHCARE UK NO 5 LTD (GB) | 2016-11-23 | — | — | EP | disclosed |
| EP-2895475-B1 | TRICYCLIC AMIDINE DERIVATIVES AS HIV ATTACHMENT INHIBITORS | VIIV HEALTHCARE UK NO 5 LTD (GB) | 2016-11-09 | — | — | EP | disclosed |
| EP-2685984-B1 | TETRACYCLIC XANTHENE DERIVATIVES AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES | MERCK SHARP & DOHME (US) | 2016-11-02 | — | — | EP | disclosed |
| US-20160311834-A1 | PSEUDOPOLYMORPHS OF AN HCV NS5A INHIBITOR AND USES THEREOF | MERCK SHARP & DOHME LLC | 2016-10-27 | — | — | US | disclosed |
| EP-3083634-A1 | FUSED TETRACYCLIC HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES | Merck Sharp & Dohme Corp. (US) | 2016-10-26 | — | — | EP | disclosed |
| EP-2758419-B1 | NOVEL BETULINIC ACID DERIVATIVES WITH ANTIVIRAL ACTIVITY | VIIV HEALTHCARE NO 5 LTD (GB) | 2016-10-19 | — | — | EP | disclosed |
| CN-103582420-B | 2 '-substituted nucleoside derivates and the method using its treatment virosis | 默沙东公司 | 2016-10-19 | — | — | CN | disclosed |
| EP-2751118-B1 | SPIRO BICYCLIC DIAMINE DERIVATIVES AS HIV ATTACHMENT INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2016-10-12 | — | — | EP | disclosed |
| EP-2576585-B1 | MODIFIED C-3 BETULINIC ACID DERIVATIVES AS HIV MATURATION INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2016-10-12 | — | — | EP | disclosed |
| US-9457039-B2 | 2′-disubstituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases | MERCK SHARP & DOHME CORP. (US) | 2016-10-04 | — | — | US | disclosed |
| US-9447116-B2 | Inhibitors of HIV replication | VIIV HEALTHCARE UK LIMITED (GB) | 2016-09-20 | — | — | US | disclosed |
| US-20160263131-A1 | TREATMENT OF HEPATIC FIBROSIS USING AN INHIBITOR OF CBP/CATENIN | KOUJI HIROYUKI (JP) | 2016-09-15 | — | — | US | disclosed |
| US-20160257697-A1 | THIOPHENE-SUBSTITUTED TETRACYCLIC COMPOUNDS AND METHODS OFUSE THEREOF FOR THE TREATMENT OF VIRAL DISEASES | MERCK SHARP & DOHME CORP. (US) | 2016-09-08 | — | — | US | disclosed |
| EP-3063140-A1 | PSEUDOPOLYMORPHS OF AN HCV NS5A INHIBITOR AND USES THEREOF | Merck Sharp & Dohme Corp. (US) | 2016-09-07 | — | — | EP | disclosed |
| US-9433621-B2 | Substituted pyridine and pyrimidine derivatives and their use in treating viral infections | MERCK SHARP & DOHME CORP. (US) | 2016-09-06 | — | — | US | disclosed |
| US-20160243128-A1 | POLYCYCLIC HETEROCYCLE DERIVATIVES AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES | MERCK SHARP & DOHME CORP. (US) | 2016-08-25 | — | — | US | disclosed |
| EP-3057590-A2 | TREATMENT OF HEPATIC FIBROSIS USING AN INHIBITOR OF CBP/CATENIN | Kouji, Hiroyuki (JP) | 2016-08-24 | — | — | EP | disclosed |
| US-9416154-B2 | 5′-substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases | MERCK SHARP & DOHME CORP. (US) | 2016-08-16 | — | — | US | disclosed |
| US-9408863-B2 | 5′-substituted nucleoside analogs and methods of use thereof for the treatment of viral diseases | MERCK SHARP & DOHME CORP. (US) | 2016-08-09 | — | — | US | disclosed |
| EP-2064180-B1 | 4,5-RING ANNULATED INDOLE DERIVATIVES FOR TREATING OR PREVENTING OF HCV AND RELATED VIRAL INFECTIONS | MERCK SHARP & DOHME (US) | 2016-07-13 | — | — | EP | disclosed |
| EP-2646439-B1 | ALKYL AMIDES AS HIV ATTACHMENT INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2016-05-25 | — | — | EP | disclosed |
| EP-2555757-B1 | ATAZANAVIR SULFATE FORMULATIONS WITH IMPROVED PH EFFECT | BRISTOL MYERS SQUIBB HOLDINGS IRELAND (CH) | 2016-05-25 | — | — | EP | disclosed |
| US-20160122380-A1 | CYCLIC PHOSPHONATE SUBSTITUTED NUCLEOSIDE DERIVATIVES AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES | MERCK SHARP & DOHME CORP. (US) | 2016-05-05 | — | — | US | disclosed |
| EP-3010512-A1 | CYCLIC PHOSPHONATE SUBSTITUTED NUCLEOSIDE DERIVATIVES AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES | Merck Sharp & Dohme Corp. (US) | 2016-04-27 | — | — | EP | disclosed |
| US-20160082102-A1 | BIFUNCTIONAL MOLECULES WITH ANTIBODY-RECRUITING AND ENTRY INHIBITORY ACTIVITY AGAINST THE HUMAN IMMUNODEFICIENCY VIRUS | UNIV YALE (US) | 2016-03-24 | — | — | US | disclosed |
| EP-1919478-B1 | COMBINATION OF HCV PROTEASE INHIBITORS WITH A SURFACTANT | MERCK SHARP & DOHME (US) | 2016-03-23 | — | — | EP | disclosed |
| US-9265773-B2 | Tetracyclic heterocycle compounds and methods of use thereof for the treatment of viral diseases | MERCK SHARP & DOHME CORP. (US) | 2016-02-23 | — | — | US | disclosed |
| US-20160045526-A1 | 2'-DISUBSTITUTED NUCLEOSIDE DERIVATIVES AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES | MERCK SHARP & DOHME CORP. (US) | 2016-02-18 | — | — | US | disclosed |
| CN-105330675-A | Inhibitors of HIV replication | VIIV HEAL THCARE UK LTD | 2016-02-17 | — | — | CN | disclosed |
| US-9254292-B2 | Fused tetracycle derivatives and methods of use thereof for the treatment of viral diseases | MERCK SHARP & DOHME CORP. (US) | 2016-02-09 | — | — | US | disclosed |
| US-9242988-B2 | 2′-cyano substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases | MERCK SHARP & DOHME CORP. (US) | 2016-01-26 | — | — | US | disclosed |
| EP-2975038-A1 | COMPOSITION AND ANTIVIRAL ACTIVITY OF SUBSTITUTED AZAINDOLEOXOACETIC PIPERAZINE DERIVATIVES | Bristol-Myers Squibb Company (US) | 2016-01-20 | — | — | EP | disclosed |
| EP-2964655-A1 | COMPOUNDS FOR THE TREATMENT OF HEPATITIS C | Bristol-Myers Squibb Company (US) | 2016-01-13 | — | — | EP | disclosed |
| EP-2801576-B1 | Composition and antiviral activity of substituted azaindoleoxoacetic piperazine derivatives | BRISTOL MYERS SQUIBB CO (US) | 2015-12-09 | — | — | EP | disclosed |
| US-20150335648-A1 | HETEROCYCLE-SUBSTITUTED TETRACYCLIC COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES | MERCK SHARP & DOHME CORP. (US) | 2015-11-26 | — | — | US | disclosed |
| US-20150336965-A1 | NOVEL ANTIVIRAL COMPOUNDS | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2015-11-26 | — | — | US | disclosed |
| EP-2945952-A1 | HETEROCYCLE-SUBSTITUED TETRACYCLIC COMPOUNDS AND METHODS OF USE THEREOF FOR TREATMENT OF VIRAL DISEASES | Merck Sharp & Dohme Corp. (US) | 2015-11-25 | — | — | EP | disclosed |
| EP-2945953-A1 | THIOPHENE-SUBSTITUTED TETRACYCLIC COMPOUNDS AND METHODS OF USE THEREOF FOR TREATMENT OF VIRAL DISEASES | Merck Sharp & Dohme Corp. (US) | 2015-11-25 | — | — | EP | disclosed |
| EP-2545060-B1 | FUSED TRICYCLIC SILYL COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES | MERCK SHARP & DOHME (US) | 2015-11-25 | — | — | EP | disclosed |
| CN-105073755-A | Heterocycle-substituted tetracyclic compounds and methods of use thereof for treatment of viral diseases | MERCK SHARP & DOHME | 2015-11-18 | — | — | CN | disclosed |
| US-9181224-B2 | Bifunctional molecules with antibody-recruiting and entry inhibitory activity against the human immunodeficiency virus | YALE UNIVERSITY (US) | 2015-11-10 | — | — | US | disclosed |
| US-20150299243-A1 | 2'-ALKYNYL SUBSTITUTED NUCLEOSIDE DERIVATIVES AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES | MERCK SHARP & DOHME CORP. (US) | 2015-10-22 | — | — | US | disclosed |
| CN-103429595-B | Inhibitors of HIV Replication | VIIV HEALTHCARE UK LTD. (GB) | 2015-10-21 | — | — | CN | disclosed |
| US-9156872-B2 | 2′-azido substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases | MERCK SHARP & DOHME CORP. (US) | 2015-10-13 | — | — | US | disclosed |
| US-9150603-B2 | 2′-cyano substituted nucleoside derivatives and methods of use thereof useful for the treatment of viral diseases | MERCK SHARP & DOHME CORP. (US) | 2015-10-06 | — | — | US | disclosed |
| US-20150274739-A1 | 2'-CYANO SUBSTITUTED NUCLEOSIDE DERIVATIVES AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES | MERCK SHARP & DOHME CORP. (US) | 2015-10-01 | — | — | US | disclosed |
| EP-2922572-A1 | USE OF SMALL MOLECULE INHIBITORS/ACTIVATORS IN COMBINATION WITH (DEOXY)NUCLEOSIDE OR (DEOXY)NUCLEOTIDE ANALOGS FOR TREATMENT OF CANCER AND HEMATOLOGICAL MALIGNANCIES OR VIRAL INFECTIONS | AB Science (FR) | 2015-09-30 | — | — | EP | disclosed |
| EP-2536410-B1 | SUBSTITUTED PYRIMIDINE DERIVATIVES AND THEIR USE IN TREATING VIRAL INFECTIONS | MERCK SHARP & DOHME (US) | 2015-09-23 | — | — | EP | disclosed |
| EP-2919792-A1 | 2 -ALKYNYL SUBSTITUTED NUCLEOSIDE DERIVATIVES FOR TREATING VIRAL DISEASES | Merck Sharp & Dohme Corp. (US) | 2015-09-23 | — | — | EP | disclosed |
| US-9139569-B2 | Fused tricyclic aryl compounds useful for the treatment of viral diseases | MERCK SHARP & DOHME CORP. (US) | 2015-09-22 | — | — | US | disclosed |
| EP-2917222-A1 | COMPOUNDS FOR THE TREATMENT OF HEPATITIS C | Bristol-Myers Squibb Company (US) | 2015-09-16 | — | — | EP | disclosed |
| CN-104918623-A | 2-alkynyl substituted nucleoside derivatives for the treatment of viral diseases | MERCK SHARP & DOHME | 2015-09-16 | — | — | CN | disclosed |
| US-9132129-B2 | Antiviral compounds | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2015-09-15 | — | — | US | disclosed |
| EP-2914263-A1 | TEC FAMILY KINASE INHIBITOR ADJUVANT THERAPY | Pharmacyclics, Inc. (US) | 2015-09-09 | — | — | EP | disclosed |
| US-20150246902-A1 | SUBSTITUED BENZOFURAN COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES | MERCK SHARP & DOHME CORP. (US) | 2015-09-03 | — | — | US | disclosed |
| EP-2670764-B1 | C-28 AMINES OF C-3 MODIFIED BETULINIC ACID DERIVATIVES AS HIV MATURATION INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2015-09-02 | — | — | EP | disclosed |
| EP-2909209-A1 | 2'-CYANO SUBSTITUTED NUCLEOSIDE DERIVATIVES AND METHODS OF USE THEREOF FOR TREATMENT OF VIRAL DISEASES | Merck Sharp & Dohme Corp. (US) | 2015-08-26 | — | — | EP | disclosed |
| EP-2909221-A1 | 2'-METHYL SUBSTITUTED NUCLEOSIDE DERIVATIVES AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES | Merck Sharp & Dohme Corp. (US) | 2015-08-26 | — | — | EP | disclosed |
| EP-2909210-A1 | 2'-DISUBSTITUTED SUBSTITUTED NUCLEOSIDE DERIVATIVES AND METHODS OF USE THEREOF FOR TREATMENT OF VIRAL DISEASES | Merck Sharp & Dohme Corp. (US) | 2015-08-26 | — | — | EP | disclosed |
| EP-2576586-B1 | C-28 AMIDES OF MODIFIED C-3 BETULINIC ACID DERIVATIVES AS HIV MATURATION INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2015-08-12 | — | — | EP | disclosed |
| CN-102770181-B | Antiviral compound | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2015-08-12 | — | — | CN | disclosed |
| WO-2015094998-A1 | FUSED TETRACYCLIC HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES | MERCK SHARP & DOHME CORP. (US) | 2015-06-25 | — | — | WO | disclosed |
| WO-2015089810-A1 | FUSED TETRACYCLIC HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES | MERCK SHARP & DOHME CORP. (US) | 2015-06-25 | — | — | WO | disclosed |
| US-9061041-B2 | 2′-substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases | MERCK SHARP & DOHME CORP. (US) | 2015-06-23 | — | — | US | disclosed |
| EP-2430015-B1 | FUSED TRICYCLIC COMPOUNDS USEFUL FOR THE TREATMENT OF VIRAL DISEASES | MERCK SHARP & DOHME (US) | 2015-06-17 | — | — | EP | disclosed |
| EP-2503881-B1 | FUSED TRICYCLIC COMPOUNDS AND DERIVATIVES THEREOF USEFUL FOR THE TREATMENT OF VIRAL DISEASES | MERCK SHARP & DOHME (US) | 2015-05-13 | — | — | EP | disclosed |
| WO-2015065817-A1 | PSEUDOPOLYMORPHS OF AN HCV NS5A INHIBITOR AND USES THEREOF | MERCK SHARP & DOHME CORP. (US) | 2015-05-07 | — | — | WO | disclosed |
| CN-104593330-A | Recombinant 293T cell containing A-type influenza specific promoter and application thereof | CHINESE ACAD INST MICROBIOLOGY | 2015-05-06 | — | — | CN | disclosed |
| WO-2015056104-A2 | TREATMENT OF HEPATIC FIBROSIS USING AN INHIBITOR OF CBP/CATENIN | KOUJI HIROYUKI (JP) | 2015-04-23 | — | — | WO | disclosed |
| US-20150087609-A1 | CYTOTOXIC-DRUG DELIVERING MOLECULES TARGETING HIV (CDM-HS), CYTOTOXIC ACTIVITY AGAINST THE HUMAN IMMUNODEFICIENCY VIRUS AND METHODS OF USE | YALE UNIVERSITY | 2015-03-26 | — | — | US | disclosed |
| CN-102159579-B | Tricyclic indole derivatives and methods of use thereof | MERCK SHARP & DOHME | 2015-03-25 | — | — | CN | disclosed |
| US-8980920-B2 | Antiviral compounds of three linked aryl moieties to treat diseases such as hepatitis C | MERCK SHARP & DOHME CORP. (US) | 2015-03-17 | — | — | US | disclosed |
| WO-2014110705-A9 | HETEROCYCLE-SUBSTITUTED TETRACYCLIC COMPOUNDS AND METHODS OF USE THEREOF FOR TREATMENT OF VIRAL DISEASES | MERCK SHARP & DOHME CORP. (US) | 2015-03-05 | — | — | WO | disclosed |
| EP-2841107-A1 | CYTOTOXIC-DRUG DELIVERING MOLECULES TARGETING HIV (CDM-HS), CYTOTOXIC ACTIVITY AGAINST THE HUMAN IMMUNODEFICIENCY VIRUS AND METHODS OF USE | Yale University (US) | 2015-03-04 | — | — | EP | disclosed |
| US-20150057246-A1 | SILYL-CONTAINING HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES | MERCK SHARP & DOHME CORP. | 2015-02-26 | — | — | US | disclosed |
| US-20150050237-A1 | NEW ANTI-MYCOBACTERIAL DRUGS AGAINST TUBERCULOSIS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2015-02-19 | — | — | US | disclosed |
| EP-2831056-A1 | NEW ANTI-MYCOBACTERIAL DRUGS AGAINST TUBERCULOSIS | The University Of Georgia Research Foundation, Inc (US) | 2015-02-04 | — | — | EP | disclosed |
| EP-2435424-B1 | ANTIVIRAL COMPOUNDS COMPOSED OF THREE LINKED ARYL MOIETIES TO TREAT DISEASES SUCH AS HEPATITIS C | MERCK SHARP & DOHME (US) | 2015-01-21 | — | — | EP | disclosed |
| US-20140377223-A1 | SUBSTITUTED BIPHENYLENE COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES | SCHERING CORPORATION | 2014-12-25 | — | — | US | disclosed |
| US-20140378416-A1 | SILYL-CONTAINING HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES | MERCK SHARP & DOHME CORP. | 2014-12-25 | — | — | US | disclosed |
| WO-2014204831-A1 | CYCLIC PHOSPHONATE SUBSTITUTED NUCLEOSIDE DERIVATIVES AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES | MERCK SHARP & DOHME CORP. (US) | 2014-12-24 | — | — | WO | disclosed |
| CN-104220067-A | Compositions useful for treating viral diseases | MERCK SHARP & DOHME | 2014-12-17 | — | — | CN | disclosed |
| US-8901139-B2 | Tricyclic indole derivatives and methods of use thereof | MERCK SHARP & DOHME CORP. (US) | 2014-12-02 | — | — | US | disclosed |
| EP-2601174-B1 | SUBSTITUTED INDOLE AND AZAINDOLE OXOACETYL PIPERAZINAMIDE DERIVATIVES | BRISTOL MYERS SQUIBB CO (US) | 2014-11-26 | — | — | EP | disclosed |
| US-8889153-B2 | Combination of immunomodulator and anti-pathogenic agent | NUNES ISEU DA SILVA (BR) | 2014-11-18 | — | — | US | disclosed |
| EP-2801576-A1 | Composition and antiviral activity of substituted azaindoleoxoacetic piperazine derivatives | Bristol-Myers Squibb Company (US) | 2014-11-12 | — | — | EP | disclosed |
| EP-1891089-B1 | HCV protease inhibitors in combination with food | MERCK SHARP & DOHME (US) | 2014-11-05 | — | — | EP | disclosed |
| EP-2516430-B1 | FUSED TRICYCLIC COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES | MERCK SHARP & DOHME (US) | 2014-11-05 | — | — | EP | disclosed |
| US-20140315927-A1 | Inhibitors of HIV Replication | VIIV HEALTHCARE UK LIMITED (GB) | 2014-10-23 | — | — | US | disclosed |
| WO-2014138239-A1 | COMPOUNDS FOR THE TREATMENT OF HEPATITIS C | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-09-12 | — | — | WO | disclosed |
| EP-2773342-A1 | COMPOSITIONS USEFUL FOR THE TREATMENT OF VIRAL DISEASES | Merck Sharp & Dohme Corp. (US) | 2014-09-10 | — | — | EP | disclosed |
| CN-103110752-B | Chinese herbal preparation for treating infant epidemic parotitis meningoencephalitis | NIU XIAOGUANG | 2014-09-03 | — | — | CN | disclosed |
| US-20140242027-A1 | SUBSTITUTED PYRIDINE AND PYRIMIDINE DERIVATIVES AND THEIR USE IN TREATING VIRAL INFECTIONS | SOUTHERN RESEARCH INSTITUTE (US) | 2014-08-28 | — | — | US | disclosed |
| US-20140235567-A1 | 5'-SUBSTITUTED NUCLEOSIDE DERIVATIVES AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES | MERCK SHARP & DOHME LLC | 2014-08-21 | — | — | US | disclosed |
| US-8809363-B2 | Inhibitors of HIV replication | VIIV HEALTHCARE UK LIMITED (GB) | 2014-08-19 | — | — | US | disclosed |
| US-20140221304-A1 | 5'-SUBSTITUTED NUCLEOSIDE ANALOGS AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES | MERCK SHARP & DOHME LLC | 2014-08-07 | — | — | US | disclosed |
| US-20140213571-A1 | TETRACYCLIC HETEROCYCLE COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES | MERCK SHARP & DOHME LLC | 2014-07-31 | — | — | US | disclosed |
| WO-2014110687-A1 | THIAZOLYL-SUBSTITUED TETRACYCLIC COMPOUNDS AND METHODS OF USE THEREOF FOR TREATMENT OF VIRAL DISEASES | MERCK SHARP & DOHME CORP. (US) | 2014-07-24 | — | — | WO | disclosed |
| WO-2014110705-A1 | HETEROCYCLE-SUBSTITUED TETRACYCLIC COMPOUNDS AND METHODS OF USE THEREOF FOR TREATMENT OF VIRAL DISEASES | MERCK SHARP & DOHME CORP. (US) | 2014-07-24 | — | — | WO | disclosed |
| WO-2014110688-A1 | THIOPHENE- SUB STITUED TETRACYCLIC COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES | MERCK SHARP & DOHME CORP. (US) | 2014-07-24 | — | — | WO | disclosed |
| WO-2014110706-A1 | THIOPHENE-SUBSTITUTED TETRACYCLIC COMPOUNDS AND METHODS OF USE THEREOF FOR TREATMENT OF VIRAL DISEASES | MERCK SHARP & DOHME CORP. (US) | 2014-07-24 | — | — | WO | disclosed |
| US-20140206640-A1 | 2'-AZIDO SUBSTITUTED NUCLEOSIDE DERIVATIVES AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES | MERCK SHARP & DOHME CORP. (US) | 2014-07-24 | — | — | US | disclosed |
| EP-2755981-A1 | SILYL-CONTAINING HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES | Merck Sharp & Dohme Corp. (US) | 2014-07-23 | — | — | EP | disclosed |
| EP-2755982-A1 | SILYL-CONTAINING HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES | Merck Sharp & Dohme Corp. (US) | 2014-07-23 | — | — | EP | disclosed |
| US-20140199264-A1 | TETRACYCLIC XANTHENE DERIVATIVES AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES | MERCK SHARP & DOHME LLC | 2014-07-17 | — | — | US | disclosed |
| US-20140199263-A1 | HETEROCYCLIC-SUBSTITUTED BENZOFURAN DERIVATIVES AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES | MERCK SHARP & DOHME LLC | 2014-07-17 | — | — | US | disclosed |
| US-8772505-B2 | Antiviral compounds composed of three aligned aryl moieties to treat diseases such as hepatitis C | MERCK SHARP & DOHME CORP. (US) | 2014-07-08 | — | — | US | disclosed |
| CN-103906512-A | Tetracyclic heterocyclic compounds and methods of use thereof for treating viral diseases | MERCK SHARP & DOHME | 2014-07-02 | — | — | CN | disclosed |
| US-8765757-B2 | 3-heterocyclic substituted indole derivatives and methods of use thereof | MERCK SHARP & DOHME CORP. (US) | 2014-07-01 | — | — | US | disclosed |
| US-20140170111-A1 | FUSED TETRACYCLE DERIVATIVES AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES | Merck Sharp & Dohmn Corp. (US) | 2014-06-19 | — | — | US | disclosed |
| US-20140161770-A1 | 2'-CYANO SUBSTITUTED NUCLEOSIDE DERIVATIVES AND METHODS OF USE THEREOF USEFUL FOR THE TREATMENT OF VIRAL DISEASES | MERCK SHARP & DOHME CORP. (US) | 2014-06-12 | — | — | US | disclosed |
| US-20140154211-A1 | 2'-SUBSTITUTED NUCLEOSIDE DERIVATIVES AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES | MERCK SHARP & DOHME LLC | 2014-06-05 | — | — | US | disclosed |
| US-8742123-B2 | HIV integrase inhibitors from pyridoxine | TAIMED BIOLOGICS, INC. (TW) | 2014-06-03 | — | — | US | disclosed |
| WO-2014079709-A1 | USE OF SMALL MOLECULE INHIBITORS/ACTIVATORS IN COMBINATION WITH (DEOXY)NUCLEOSIDE OR (DEOXY)NUCLEOTIDE ANALOGS FOR TREATMENT OF CANCER AND HEMATOLOGICAL MALIGNANCIES OR VIRAL INFECTIONS | AB SCIENCE (FR) | 2014-05-30 | — | — | WO | disclosed |
| WO-2014078463-A1 | 2 -ALKYNYL SUBSTITUTED NUCLEOSIDE DERIVATIVES FOR TREATING VIRAL DISEASES | MERCK SHARP & DOHME CORP. (US) | 2014-05-22 | — | — | WO | disclosed |
| EP-2731433-A1 | 5'-SUBSTITUTED NUCLEOSIDE ANALOGS AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES | Merck Sharp & Dohme Corp. (US) | 2014-05-21 | — | — | EP | disclosed |
| EP-2731434-A1 | 5'-SUBSTITUTED NUCLEOSIDE DERIVATIVES AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES | Merck Sharp & Dohme Corp. (US) | 2014-05-21 | — | — | EP | disclosed |
| EP-2497770-B1 | Composition and antiviral activity of substituted azaindoleoxoacetic piperazine derivatives | BRISTOL MYERS SQUIBB CO (US) | 2014-05-14 | — | — | EP | disclosed |
| US-20140128339-A1 | 2'-METHYL SUBSTITUTED NUCLEOSIDE DERIVATIVES AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES | MERCK SHARP & DOHME CORP. | 2014-05-08 | — | — | US | disclosed |
| WO-2014071231-A1 | TEC FAMILY KINASE INHIBITOR ADJUVANT THERAPY | PHARMACYCLICS, INC. (US) | 2014-05-08 | — | — | WO | disclosed |
| US-8715638-B2 | Ethenyl-substituted pyridine and pyrimidine derivatives and their use in treating viral infections | MERCK SHARP & DOHME CORP. (US) | 2014-05-06 | — | — | US | disclosed |
| WO-2014062596-A1 | 2'-METHYL SUBSTITUTED NUCLEOSIDE DERIVATIVES AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES | MERCK SHARP & DOHME CORP. (US) | 2014-04-24 | — | — | WO | disclosed |
| WO-2014059902-A1 | 2'-DISUBSTITUTED SUBSTITUTED NUCLEOSIDE DERIVATIVES AND METHODS OF USE THEREOF FOR TREATMENT OF VIRAL DISEASES | MERCK SHARP & DOHME CORP. (US) | 2014-04-24 | — | — | WO | disclosed |
| WO-2014059901-A1 | 2'-CYANO SUBSTITUTED NUCLEOSIDE DERIVATIVES AND METHODS OF USE THEREOF FOR TREATMENT OF VIRAL DISEASES | MERCK SHARP & DOHME CORP. (US) | 2014-04-24 | — | — | WO | disclosed |
| WO-2014062636-A1 | COMPOUNDS FOR THE TREATMENT OF HEPATITIS C | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-04-24 | — | — | WO | disclosed |
| EP-2509949-B1 | PYRIDINONE HYDROXYCYCLOPENTYL CARBOXAMIDES: HIV INTEGRASE INHIBITORS WITH THERAPEUTIC APPLICATIONS | UNIV GEORGIA (US) | 2014-04-23 | — | — | EP | disclosed |
| EP-2280981-B1 | BRIDGED HETEROCYCLES AS HIV INTEGRASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2014-04-23 | — | — | EP | disclosed |
| US-8703801-B2 | Pyridinone hydroxycyclopentyl carboxamides: HIV integrase inhibitors with therapeutic applications | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 2014-04-22 | — | — | US | disclosed |
| EP-2516008-B1 | NOVEL ANTIVIRAL COMPOUNDS | UNIV LEUVEN KATH (BE) | 2014-04-16 | — | — | EP | disclosed |
| CN-103732242-A | Treatment of chronic hepatitis C with IFN-alpha 5 in combination with IFN-alpha 2b in a patient population | DIGNA BIOTECH SL | 2014-04-16 | — | — | CN | disclosed |
| US-8697694-B2 | Substituted pyridine and pyrimidine derivatives and their use in treating viral infections | MERCK SHARP & DOHME CORP. (US) | 2014-04-15 | — | — | US | disclosed |
| EP-2222660-B1 | 3-HETEROCYCLIC SUBSTITUTED INDOLE DERIVATIVES AND METHODS OF USE THEREOF | MERCK SHARP & DOHME (US) | 2014-03-26 | — | — | EP | disclosed |
| EP-2259799-B1 | COMBINATION OF IMMUNOMODULATOR AND ANTI-PATHOGENIC AGENT | NUNES ISEU DA SILVA (BR) | 2014-03-12 | — | — | EP | disclosed |
| EP-1513832-B1 | Indole, azaindole and related heterocyclic 4-alkenyl piperidine amides | BRISTOL MYERS SQUIBB CO (US) | 2014-03-05 | — | — | EP | disclosed |
| EP-2696679-A2 | 2'-CYANO SUBSTITUTED NUCLEOSIDE DERIVATIVES AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES | Merck Sharp & Dohme Corp. (US) | 2014-02-19 | — | — | EP | disclosed |
| EP-2696681-A1 | 2'-SUBSTITUTED NUCLEOSIDE DERIVATIVES AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES | Merck Sharp & Dohme Corp. (US) | 2014-02-19 | — | — | EP | disclosed |
| EP-2697233-A1 | MACROCYCLIC TRIAZINE COMPOUNDS FOR THE TREATMENT OF HEPATITIS C | Bristol-Myers Squibb Company (US) | 2014-02-19 | — | — | EP | disclosed |
| EP-2697230-A1 | COMPOUNDS FOR THE TREATMENT OF HEPATITIS C | Bristol-Myers Squibb Company (US) | 2014-02-19 | — | — | EP | disclosed |
| EP-2697242-A1 | 2'-AZIDO SUBSTITUTED NUCLEOSIDE DERIVATIVES AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES | Merck Sharp & Dohme Corp. (US) | 2014-02-19 | — | — | EP | disclosed |
| EP-2685984-A2 | TETRACYCLIC XANTHENE DERIVATIVES AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES | Merck Sharp & Dohme Corp. (US) | 2014-01-22 | — | — | EP | disclosed |
| EP-2170292-B1 | TABLETED COMPOSITIONS CONTAINING ATAZANAVIR | BRISTOL MYERS SQUIBB HOLDINGS IRELAND (CH) | 2014-01-08 | — | — | EP | disclosed |
| US-8614229-B2 | Substituted indole derivatives and methods of use thereof | MERCK SHARP & DOHME CORP. (US) | 2013-12-24 | — | — | US | disclosed |
| EP-2222672-B1 | 3-AMINOSULFONYL SUBSTITUTED INDOLE DERIVATIVES AND METHODS OF USE THEREOF | MERCK SHARP & DOHME (US) | 2013-12-18 | — | — | EP | disclosed |
| CN-103459399-A | Tetracyclic indole derivatives for the treatment of hepatitis C virus infection | MERCK SHARP & DOHME | 2013-12-18 | — | — | CN | disclosed |
| US-8609635-B2 | Fused tricyclic silyl compounds and methods of use thereof for the treatment of viral diseases | MERCK SHARP & DOHME CORP. (US) | 2013-12-17 | — | — | US | disclosed |
| EP-1575493-B1 | INDOLE, AZAINDOLE AND RELATED HETEROCYCLIC SULFONYLUREIDO PIPERAZINE DERIVATIVES | BRISTOL MYERS SQUIBB CO (US) | 2013-12-11 | — | — | EP | disclosed |
| CN-103429595-A | Inhibitors of hiv replication | VIIV HEALTHCARE UK LTD | 2013-12-04 | — | — | CN | disclosed |
| CN-103391924-A | Novel antiviral compounds | UNIV LEUVEN KATH | 2013-11-13 | — | — | CN | disclosed |
| WO-2013162757-A1 | CYTOTOXIC-DRUG DELIVERING MOLECULES TARGETING HIV (CDM-HS), CYTOTOXIC ACTIVITY AGAINST THE HUMAN IMMUNODEFICIENCY VIRUS AND METHODS OF USE | YALE UNIVERSITY (US) | 2013-10-31 | — | — | WO | disclosed |
| US-20130280214-A1 | POLYCYCLIC HETEROCYCLE DERIVATIVES AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES | MERCK SHARP & DOHME CORP. (US) | 2013-10-24 | — | — | US | disclosed |
| EP-2326626-B1 | ETHENYL-SUBSTITUTED PYRIDINE AND PYRIMIDINE DERIVATIVES AND THEIR USE IN TREATING VIRAL INFECTIONS | MERCK SHARP & DOHME (US) | 2013-10-16 | — | — | EP | disclosed |
| US-8557848-B2 | 4,5-ring annulated indole derivatives for treating or preventing of HCV and related viral infections | MERCK SHARP & DOHME CORP. (US) | 2013-10-15 | — | — | US | disclosed |
| WO-2013148174-A1 | NEW ANTI-MYCOBACTERIAL DRUGS AGAINST TUBERCULOSIS | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 2013-10-03 | — | — | WO | disclosed |
| US-8546420-B2 | 4, 5-ring annulated indole derivatives for treating or preventing of HCV and related viral infections | MERCK SHARP & DOHME CORP. (US) | 2013-10-01 | — | — | US | disclosed |
| EP-2640705-A2 | NOVEL ANTIVIRAL COMPOUNDS | Katholieke Universiteit Leuven (BE) | 2013-09-25 | — | — | EP | disclosed |
| EP-2640720-A2 | BIFUNCTIONAL MOLECULES WITH ANTIBODY-RECRUITING AND ENTRY INHIBITORY ACTIVITY AGAINST THE HUMAN IMMUNODEFICIENCY VIRUS | Yale University, Inc. (US) | 2013-09-25 | — | — | EP | disclosed |
| EP-2640729-A1 | INHIBITORS OF HIV REPLICATION | VIIV Healthcare UK Limited (GB) | 2013-09-25 | — | — | EP | disclosed |
| US-8541434-B2 | Ethynyl-substituted pyridine and pyrimidine derivatives and their use in treating viral infections | MERCK SHARP & DOHME CORP. (US) | 2013-09-24 | — | — | US | disclosed |
| US-20130245049-A1 | Novel Antiviral Compounds | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2013-09-19 | — | — | US | disclosed |
| US-20130245040-A1 | BIFUNCTIONAL MOLECULES WITH ANTIBODY-RECRUITING AND ENTRY INHIBITORY ACTIVITY AGAINST THE HUMAN IMMUNODEFICIENCY VIRUS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2013-09-19 | — | — | US | disclosed |
| EP-2010525-B1 | Diketo-piperazine and piperidine derivatives as antiviral agents | BRISTOL MYERS SQUIBB CO (US) | 2013-08-28 | — | — | EP | disclosed |
| EP-2621501-A1 | POLYCYCLIC HETEROCYCLE DERIVATIVES AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES | Merck Sharp & Dohme Corp. (US) | 2013-08-07 | — | — | EP | disclosed |
| EP-2621932-A1 | TETRACYCLIC HETEROCYCLE COMPOUNDS FOR TREATING HEPATITIS C VIRAL INFECTION | Merck Sharp & Dohme Corp. (US) | 2013-08-07 | — | — | EP | disclosed |
| EP-2621279-A1 | FUSED TETRACYCLE DERIVATIVES AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES | Merck Sharp & Dohme Corp. (US) | 2013-08-07 | — | — | EP | disclosed |
| EP-2621931-A1 | TETRACYCLIC INDOLE DERIVATIVES FOR TREATING HEPATITIS C VIRUS INFECTION | Merck Sharp & Dohme Corp. (US) | 2013-08-07 | — | — | EP | disclosed |
| WO-2012068366-A9 | BIFUNCTIONAL MOLECULES WITH ANTIBODY-RECRUITING AND ENTRY INHIBITORY ACTIVITY AGAINST THE HUMAN IMMUNODEFICIENCY VIRUS | YALE UNIVERSITY (US) | 2013-07-18 | — | — | WO | disclosed |
| US-20130164259-A1 | 1,4-SUBSTITUTED PIPERAZINE DERIVATIVES AND METHODS OF USE THEREOF | SCHERING CORPORATION | 2013-06-27 | — | — | US | disclosed |
| US-20130164258-A1 | Antiviral Compounds Composed of Three Aligned Aryl Moieties to Treat Diseases such as Hepatitis C | MERCK SHARP & DOHME LLC | 2013-06-27 | — | — | US | disclosed |
| US-8470834-B2 | AZO-substituted pyridine and pyrimidine derivatives and their use in treating viral infections | MERCK SHARP & DOHME CORP. (US) | 2013-06-25 | — | — | US | disclosed |
| US-20130156731-A1 | FUSED TRICYCLIC COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEAS | SCHERING CORPORATION | 2013-06-20 | — | — | US | disclosed |
| EP-2598149-A2 | SUBSTITUTED BIPHENYLENE COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES | Merck Sharp & Dohme Corp. (US) | 2013-06-05 | — | — | EP | disclosed |
| CN-103110752-A | Chinese herbal preparation for treating infant epidemic parotitis meningoencephalitis | NIU XIAOGUANG | 2013-05-22 | — | — | CN | disclosed |
| WO-2013066753-A1 | COMPOSITIONS USEFUL FOR THE TREATMENT OF VIRAL DISEASES | MERCK SHARP & DOHME CORP. (US) | 2013-05-10 | — | — | WO | disclosed |
| EP-2588464-A1 | BENZOFURAN DERIVATIVES FOR THE TREATMENT OF HEPATITS C | Bristol-Myers Squibb Company (US) | 2013-05-08 | — | — | EP | disclosed |
| US-8404845-B2 | 2,3-substituted azaindole derivatives for treating viral infections | MERCK SHARP & DOHME CORP. (US) | 2013-03-26 | — | — | US | disclosed |
| WO-2013039876-A1 | SILYL-CONTAINING HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES | MERCK SHARP & DOHME CORP. (US) | 2013-03-21 | — | — | WO | disclosed |
| WO-2013039878-A1 | SILYL-CONTAINING HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES | MERCK SHARP & DOHME CORP. (US) | 2013-03-21 | — | — | WO | disclosed |
| WO-2013033901-A1 | HETEROCYCLIC-SUBSTITUTED BENZOFURAN DERIVATIVES AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES | MERCK SHARP & DOHME CORP. (US) | 2013-03-14 | — | — | WO | disclosed |
| WO-2013033971-A1 | TETRACYCLIC HETEROCYCLE COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES | MERCK SHARP & DOHME CORP. (US) | 2013-03-14 | — | — | WO | disclosed |
| WO-2013033899-A1 | SUBSTITUTED BENZOFURAN COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES | MERCK SHARP & DOHME CORP. (US) | 2013-03-14 | — | — | WO | disclosed |
| WO-2013034048-A1 | SUBSTITUTED BENZOFURAN COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES | MERCK SHARP & DOHME CORP. (US) | 2013-03-14 | — | — | WO | disclosed |
| WO-2013034047-A1 | HETEROCYCLIC-SUBSTITUED BENZOFURAN DERIVATIVES AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES | MERCK SHARP & DOHME CORP. (US) | 2013-03-14 | — | — | WO | disclosed |
| WO-2013033900-A1 | TETRACYCLIC HETEROCYCLE COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES | MERCK SHARP & DOHME CORP. (US) | 2013-03-14 | — | — | WO | disclosed |
| EP-2566872-A1 | COMPOUNDS FOR THE TREATMENT OF HEPATITIS C | Bristol-Myers Squibb Company (US) | 2013-03-13 | — | — | EP | disclosed |
| EP-2561365-A2 | METHODS OF IDENTIFYING & USING ANTI-VIRAL COMPOUNDS | Kineta, Inc. (US) | 2013-02-27 | — | — | EP | disclosed |
| US-8377928-B2 | 3-aminosulfonyl substituted indole derivatives and methods of use thereof | MERCK SHARP & DOHME CORP. (US) | 2013-02-19 | — | — | US | disclosed |
| CN-102918049-A | Fused tricyclic silyl compounds and methods of use thereof for treating viral diseases | MERCK SHARP & DOHME | 2013-02-06 | — | — | CN | disclosed |
| WO-2013009735-A1 | 5'-SUBSTITUTED NUCLEOSIDE DERIVATIVES AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES | MERCK SHARP & DOHME CORP. (US) | 2013-01-17 | — | — | WO | disclosed |
| WO-2013009737-A1 | 5'-SUBSTITUTED NUCLEOSIDE ANALOGS AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES | MERCK SHARP & DOHME CORP. (US) | 2013-01-17 | — | — | WO | disclosed |
| EP-2545050-A1 | COMPOUNDS FOR THE TREATMENT OF HEPATITIS C | Bristol-Myers Squibb Company (US) | 2013-01-16 | — | — | EP | disclosed |
| EP-2545042-A1 | COMPOUNDS FOR THE TREATMENT OF HEPATITIS C | Bristol-Myers Squibb Company (US) | 2013-01-16 | — | — | EP | disclosed |
| EP-2545060-A1 | FUSED TRICYCLIC SILYL COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES | Merck Sharp & Dohme Corp. (US) | 2013-01-16 | — | — | EP | disclosed |
| EP-2545051-A1 | COMPOUNDS FOR THE TREATMENT OF HEPATITIS C | Bristol-Myers Squibb Company (US) | 2013-01-16 | — | — | EP | disclosed |
| EP-2539340-A1 | PYRAZOLOPYRIDAZINE DERIVATIVES FOR THE TREATMENT OF HEPATITIS C | Bristol-Myers Squibb Company (US) | 2013-01-02 | — | — | EP | disclosed |
| WO-2012175700-A1 | TREATMENT OF CHRONIC HEPATITIS C WITH IFN-A5 COMBINED WITH IFN-A2B IN A COHORT OF PATIENTS | DIGNA BIOTECH, S. L. (ES) | 2012-12-27 | — | — | WO | disclosed |
| EP-2536410-A1 | SUBSTITUTED PYRIDINE AND PYRIMIDINE DERIVATIVES AND THEIR USE IN TREATING VIRAL INFECTIONS | Merck Sharp & Dohme Corp. (US) | 2012-12-26 | — | — | EP | disclosed |
| CN-102031305-B | Recombinant cell containing influenza A specific promoter and application thereof | CHINESE ACAD INST MICROBIOLOGY | 2012-12-19 | — | — | CN | disclosed |
| US-20120316161-A1 | NOVEL ANTIVIRAL COMPOUNDS | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2012-12-13 | — | — | US | disclosed |
| US-20120295843-A1 | COMBINATION THERAPY FOR THE TREATMENT OF HCV INFECTION | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-11-22 | — | — | US | disclosed |
| WO-2012154353-A1 | MACROCYCLIC TRIAZINE COMPOUNDS FOR THE TREATMENT OF HEPATITIS C | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-11-15 | — | — | WO | disclosed |
| US-20120282218-A1 | PYRIDINONE HYDROXYCYCLOPENTYL CARBOXAMIDES: HIV INTEGRASE INHIBITORS WITH THERAPEUTIC APPLICATIONS | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION INC. (US) | 2012-11-08 | — | — | US | disclosed |
| CN-102770181-A | Novel antiviral compounds | UNIV LEUVEN KATH | 2012-11-07 | — | — | CN | disclosed |
| US-20120276047-A1 | FUSED TRICYCLIC COMPOUNDS AND DERIVATIVES THEREOF USEFUL FOR THE TREATMENT OF VIRAL DISEASES | SCHERING CORPORATION | 2012-11-01 | — | — | US | disclosed |
| EP-2515908-A2 | 1,4-SUBSTITUTED PIPERAZINE DERIVATIVES AND METHODS OF USE THEREOF | Merck Sharp & Dohme Corp. (US) | 2012-10-31 | — | — | EP | disclosed |
| EP-2516430-A1 | FUSED TRICYCLIC COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES | Merck Sharp & Dohme Corp. (US) | 2012-10-31 | — | — | EP | disclosed |
| EP-2516008-A1 | NOVEL ANTIVIRAL COMPOUNDS | Katholieke Universiteit Leuven (BE) | 2012-10-31 | — | — | EP | disclosed |
| US-20120269766-A1 | BIFUNCTIONAL MOLECULES WITH ANTIBODY-RECRUITING AND ENTRY INHIBITORY ACTIVITY AGAINST THE HUMAN IMMUNODEFICIENCY VIRUS | YALE UNIVERSITY (US) | 2012-10-25 | — | — | US | disclosed |
| WO-2012142085-A1 | 2'-SUBSTITUTED NUCLEOSIDE DERIVATIVES AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES | MERCK SHARP & DOHME CORP. (US) | 2012-10-18 | — | — | WO | disclosed |
| WO-2012142075-A1 | 2'-AZIDO SUBSTITUTED NUCLEOSIDE DERIVATIVES AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES | MERCK SHARP & DOHME CORP. (US) | 2012-10-18 | — | — | WO | disclosed |
| WO-2012142093-A2 | 2'-CYANO SUBSTITUTED NUCLEOSIDE DERIVATIVES AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES | MERCK SHARP & DOHME CORP. (US) | 2012-10-18 | — | — | WO | disclosed |
| WO-2012141704-A1 | COMPOUNDS FOR THE TREATMENT OF HEPATITIS C | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-10-18 | — | — | WO | disclosed |
| EP-2509949-A2 | PYRIDINONE HYDROXYCYCLOPENTYL CARBOXAMIDES: HIV INTEGRASE INHIBITORS WITH THERAPEUTIC APPLICATIONS | University Of Georgia Research Foundation, Inc. (US) | 2012-10-17 | — | — | EP | disclosed |
| WO-2012138911-A2 | CONJUGATES OF ANTI-HIV DRUGS AND SOMATOSTATIN ANALOGS | THE ADMINISTRATORS OF THE TULANE EDUCATIONAL FUND (US) | 2012-10-11 | — | — | WO | disclosed |
| US-20120258078-A1 | ANTIVIRAL COMPOUNDS OF THREE LINKED ARYL MOIETIES TO TREAT DISEASES SUCH AS HEPATITIS C | SCHERING CORPORATION (US) | 2012-10-11 | — | — | US | disclosed |
| US-20120251491-A1 | FUSED TRICYCLIC ARYL COMPOUNDS USEFUL FOR THE TREATMENT OF VIRAL DISEASES | MERCK SHARP & DOHME LLC | 2012-10-04 | — | — | US | disclosed |
| EP-2503881-A1 | FUSED TRICYCLIC COMPOUNDS AND DERIVATIVES THEREOF USEFUL FOR THE TREATMENT OF VIRAL DISEASES | Merck Sharp & Dohme Corp. (US) | 2012-10-03 | — | — | EP | disclosed |
| WO-2012122716-A1 | TETRACYCLIC XANTHENE DERIVATIVES AND METHODS OF USE THEREOF FOR TREATMENT OF VIRAL DISEASES | MERCK SHARP & DOHME CORP. (US) | 2012-09-20 | — | — | WO | disclosed |
| WO-2012125926-A2 | TETRACYCLIC XANTHENE DERIVATIVES AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES | MERCK SHARP & DOHME CORP (US) | 2012-09-20 | — | — | WO | disclosed |
| US-8268803-B2 | 5, 6-ring annulated indole derivatives and use thereof | MERCK SHARP & DOHME CORP. (US) | 2012-09-18 | — | — | US | disclosed |
| EP-2497770-A1 | Composition and antiviral activity of substituted azaindoleoxoacetic piperazine derivatives | Bristol-Myers Squibb Company (US) | 2012-09-12 | — | — | EP | disclosed |
| EP-2494991-A1 | Combination therapy for the treatment of HCV infection | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-09-05 | — | — | EP | disclosed |
| US-8258116-B2 | Combination therapy for the treatment of HCV infection | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-09-04 | — | — | US | disclosed |
| EP-2488526-A1 | COMPOUNDS FOR THE TREATMENT OF HEPATITIS C | Bristol-Myers Squibb Company (US) | 2012-08-22 | — | — | EP | disclosed |
| EP-1919921-B1 | BICYCLIC HETEROCYCLES AS HIV INTEGRASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2012-06-27 | — | — | EP | disclosed |
| EP-2013170-B1 | 4-SQUARYLPIPERAZINE DERIVATIVES AS ANTIVIRAL AGENTS | BRISTOL MYERS SQUIBB CO (US) | 2012-06-27 | — | — | EP | disclosed |
| EP-2029532-B1 | Piperazine enamines as antiviral agents | BRISTOL MYERS SQUIBB CO (US) | 2012-06-06 | — | — | EP | disclosed |
| US-20120136023-A1 | Inhibitors of HIV Replication | VIIV HEALTHCARE UK LIMITED (GB) | 2012-05-31 | — | — | US | disclosed |
| WO-2012066442-A1 | INHIBITORS OF HIV REPLICATION | PFIZER LIMITED (GB) | 2012-05-24 | — | — | WO | disclosed |
| WO-2012065963-A2 | NOVEL ANTIVIRAL COMPOUNDS | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2012-05-24 | — | — | WO | disclosed |
| WO-2012068366-A2 | BIFUNCTIONAL MOLECULES WITH ANTIBODY-RECRUITING AND ENTRY INHIBITORY ACTIVITY AGAINST THE HUMAN IMMUNODEFICIENCY VIRUS | YALE UNIVERSITY (US) | 2012-05-24 | — | — | WO | disclosed |
| EP-2197842-B1 | 2, 3-SUBSTITUTED INDOLE DERIVATIVES FOR TREATING VIRAL INFECTIONS | SCHERING CORP (US) | 2012-05-23 | — | — | EP | disclosed |
| US-20120107271-A1 | ETHYNYL-SUBSTITUTED PYRIDINE AND PYRIMIDINE DERIVATIVES AND THEIR USE IN TREATING VIRAL INFECTIONS | MERCK SHARP & DOHME LLC | 2012-05-03 | — | — | US | disclosed |
| WO-2012051492-A2 | COMPOUNDS AND METHODS FOR INHIBITING HIV LATENCY | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 2012-04-19 | — | — | WO | disclosed |
| WO-2012050848-A1 | FUSED TETRACYCLE DERIVATIVES AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES | SCHERING CORPORATION (US) | 2012-04-19 | — | — | WO | disclosed |
| WO-2012050850-A1 | POLYCYCLIC HETEROCYCLE DERIVATIVES AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES | MERCK SHARP & DOHME CORP. (US) | 2012-04-19 | — | — | WO | disclosed |
| WO-2012040923-A1 | TETRACYCLIC INDOLE DERIVATIVES AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES | MERCK SHARP & DOHME CORP. (US) | 2012-04-05 | — | — | WO | disclosed |
| WO-2012040924-A1 | FUSED TETRACYCLIC HETEROCYCLE COMPOUNDS AND METHODS OF USE THEREOF FOR TREATMENT OF VIRAL DISEASES | MERCK SHARP & DOHME CORP. (US) | 2012-04-05 | — | — | WO | disclosed |
| WO-2012041014-A1 | TETRACYCLIC INDOLE DERIVATIVES FOR TREATING HEPATITIS C VIRUS INFECTION | MERCK SHARP & DOHME CORP. (US) | 2012-04-05 | — | — | WO | disclosed |
| WO-2012041227-A1 | TETRACYCLIC HETEROCYCLE COMPOUNDS FOR TREATING HEPATITIS C VIRAL INFECTION | MERCK SHARP & DOHME CORP. (US) | 2012-04-05 | — | — | WO | disclosed |
| EP-2435424-A1 | ANTIVIRAL COMPOUNDS COMPOSED OF THREE LINKED ARYL MOIETIES TO TREAT DISEASES SUCH AS HEPATITIS C | Schering Corporation (US) | 2012-04-04 | — | — | EP | disclosed |
| EP-2435421-A1 | ANTIVIRAL COMPOUNDS COMPOSED OF THREE ALIGNED ARYL MOIETIES TO TREAT DISEASES SUCH AS HEPATITIS C | Schering Corporation (US) | 2012-04-04 | — | — | EP | disclosed |
| US-8143305-B2 | 2,3-substituted indole derivatives for treating viral infections | SCHERING CORPORATION (US) | 2012-03-27 | — | — | US | disclosed |
| EP-2430015-A1 | FUSED TRICYCLIC ARYL COMPOUNDS USEFUL FOR THE TREATMENT OF VIRAL DISEASES | Schering Corporation (US) | 2012-03-21 | — | — | EP | disclosed |
| WO-2012003030-A9 | METHODS OF IDENTIFYING & USING ANTI-VIRAL COMPOUNDS | Kineta, Inc. (US) | 2012-03-15 | — | — | WO | disclosed |
| EP-2142215-B1 | COMBINATION THERAPY FOR THE TREATMENT OF HCV INFECTION | VERTEX PHARMA (US) | 2012-03-07 | — | — | EP | disclosed |
| EP-2419727-A1 | INTERFERON-ALFA SENSITIVITY BIOMARKERS | Schering Corporation (US) | 2012-02-22 | — | — | EP | disclosed |
| US-8119602-B2 | Administration of HCV protease inhibitors in combination with food to improve bioavailability | SCHERING CORPORATION (US) | 2012-02-21 | — | — | US | disclosed |
| WO-2012018534-A2 | SUBSTITUTED BIPHENYLENE COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES | SCHERING CORPORATION (US) | 2012-02-09 | — | — | WO | disclosed |
| EP-2081922-B1 | 5,6-Ring annulated indole derivatives and use thereof | SCHERING CORP (US) | 2012-02-01 | — | — | EP | disclosed |
| EP-2408761-A1 | SUBSTITUTED INDOLE DERIVATIVES AND METHODS OF USE THEREOF | Schering Corporation (US) | 2012-01-25 | — | — | EP | disclosed |
| EP-2195317-B1 | 2,3-SUBSTITUTED AZAINDOLE DERIVATIVES FOR TREATING VIRAL INFECTIONS | SCHERING CORP (US) | 2012-01-18 | — | — | EP | disclosed |
| WO-2012003642-A1 | FUSED TRICYCLIC COMPOUNDS AND USE THEREOF FOR TREATING VIRAL DISEASES | MERCK SHARP & DOHME CORP. (US) | 2012-01-12 | — | — | WO | disclosed |
| CN-102317285-A | Substituted indole derivatives of 3-amino-sulfonyl and method of use thereof | SCHERING CORP | 2012-01-11 | — | — | CN | disclosed |
| WO-2012003164-A1 | BENZOFURAN DERIVATIVES FOR THE TREATMENT OF HEPATITS C | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-01-05 | — | — | WO | disclosed |
| WO-2012003030-A2 | METHODS OF IDENTIFYING & USING ANTI-VIRAL COMPOUNDS | Kineta, Inc. (US) | 2012-01-05 | — | — | WO | disclosed |
| US-20110318305-A1 | SUBSTITUTED PYRIDINE AND PYRIMIDINE DERIVATIVES AND THEIR USE IN TREATING VIRAL INFECTIONS | MERCK SHARP & DOHME LLC | 2011-12-29 | — | — | US | disclosed |
| US-20110286965-A1 | ETHENYL-SUBSTITUTED PYRIDINE AND PYRIMIDINE DERIVATIVES AND THEIR USE IN TREATING VIRAL INFECTIONS | MERCK SHARP & DOHME LLC | 2011-11-24 | — | — | US | disclosed |
| US-20110286964-A1 | AZO-SUBSTITUTED PYRIDINE AND PYRIMIDINE DERIVATIVES AND THEIR USE IN TREATING VIRAL INFECTIONS | MERCK SHARP & DOHME LLC | 2011-11-24 | — | — | US | disclosed |
| EP-1943221-B1 | PIPERAZINE AMIDINES AS ANTIVIRAL AGENTS | BRISTOL MYERS SQUIBB CO (US) | 2011-11-23 | — | — | EP | disclosed |
| WO-2011139513-A1 | COMPOUNDS FOR THE TREATMENT OF HEPATITIS C | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-11-10 | — | — | WO | disclosed |
| WO-2011133719-A2 | ANTI-VIRAL COMPOUNDS | Kineta, Inc. (US) | 2011-10-27 | — | — | WO | disclosed |
| US-20110223134-A1 | FUSED TRICYCLIC SILYL COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES | MERCK SHARP & DOHME LLC | 2011-09-15 | — | — | US | disclosed |
| WO-2011112186-A1 | COMPOUNDS FOR THE TREATMENT OF HEPATITIS C | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-09-15 | — | — | WO | disclosed |
| WO-2011112769-A1 | COMPOUNDS FOR THE TREATMENT OF HEPATITIS C | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-09-15 | — | — | WO | disclosed |
| WO-2011112429-A1 | FUSED TRICYCLIC SILYL COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES | SCHERING CORPORATION (US) | 2011-09-15 | — | — | WO | disclosed |
| WO-2011112191-A1 | COMPOUNDS FOR THE TREATMENT OF HEPATITIS C | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-09-15 | — | — | WO | disclosed |
| WO-2011106340-A1 | PYRAZOLOPYRIDAZINE DERIVATIVES FOR THE TREATMENT OF HEPATITIS C | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-09-01 | — | — | WO | disclosed |
| WO-2011103441-A1 | SUBSTITUTED PYRIDINE AND PYRIMIDINE DERIVATIVES AND THEIR USE IN TREATING VIRAL INFECTIONS | SCHERING CORPORATION (US) | 2011-08-25 | — | — | WO | disclosed |
| CN-102159579-A | Tricyclic indole derivatives and methods of use thereof | SCHERING CORP | 2011-08-17 | — | — | CN | disclosed |
| US-20110189127-A1 | TRICYCLIC INDOLE DERIVATIVES AND METHODS OF USE THEREOF | MERCK SHARP & DOHME LLC | 2011-08-04 | — | — | US | disclosed |
| US-20110184028-A1 | DERIVATIVES OF PYRIDOXINE FOR INHIBITING HIV INTEGRASE | TAIMED BIOLOGICS, INC. (TW) | 2011-07-28 | — | — | US | disclosed |
| EP-1638568-B1 | INDOLE, AZAINDOLE AND RELATED HETEROCYCLIC N-SUBSTITUTED PIPERAZINE DERIVATIVES | BRISTOL MYERS SQUIBB CO (US) | 2011-07-27 | — | — | EP | disclosed |
| US-20110178120-A1 | HIV INTEGRASE INHIBITORS FROM PYRIDOXINE | AMBRILIA BIOPHARMA, INC. (CA) | 2011-07-21 | — | — | US | disclosed |
| WO-2011087740-A1 | FUSED TRICYCLIC COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES | SCHERING CORPORATION (US) | 2011-07-21 | — | — | WO | disclosed |
| WO-2011087738-A2 | 1,4-SUBSTITUTED PIPERAZINE DERIVATIVES AND METHODS OF USE THEREOF | SCHERING CORPORATION (US) | 2011-07-21 | — | — | WO | disclosed |
| CN-101317577-B | Medicament for preventing and controlling plant virus disease | TAI AN XIANHE AGRICULTURAL TECHNOLOGY INST | 2011-07-13 | — | — | CN | disclosed |
| US-20110165118-A1 | 3-HETEROCYCLIC SUBSTITUTED INDOLE DERIVATIVES AND METHODS OF USE THEREOF | SCHERING CORPORATION | 2011-07-07 | — | — | US | disclosed |
| WO-2011076765-A1 | NOVEL ANTIVIRAL COMPOUNDS | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2011-06-30 | — | — | WO | disclosed |
| US-7968718-B2 | Process for preparing triazole substituted azaindoleoxoacetic piperazine derivatives and novel salt forms produced therein | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-06-28 | — | — | US | disclosed |
| WO-2011071849-A2 | PYRIDINONE HYDROXYCYCLOPENTYL CARBOXAMIDES: HIV INTEGRASE INHIBITORS WITH THERAPEUTIC APPLICATIONS | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 2011-06-16 | — | — | WO | disclosed |
| EP-2331511-A1 | ETHYNYL-SUBSTITUTED PYRIDINE AND PYRIMIDINE DERIVATIVES AND THEIR USE IN TREATING VIRAL INFECTIONS | Schering Corporation (US) | 2011-06-15 | — | — | EP | disclosed |
| CN-102099351-A | 3-heterocyclic substituted indole derivatives and methods of use thereof | SCHERING CORP | 2011-06-15 | — | — | CN | disclosed |
| WO-2011066241-A1 | FUSED TRICYCLIC COMPOUNDS AND DERIVATIVES THEREOF USEFUL FOR THE TREATMENT OF VIRAL DISEASES | SCHERING CORPORATION (US) | 2011-06-03 | — | — | WO | disclosed |
| EP-2326626-A1 | ETHENYL-SUBSTITUTED PYRIDINE AND PYRIMIDINE DERIVATIVES AND THEIR USE IN TREATING VIRAL INFECTIONS | Schering Corporation (US) | 2011-06-01 | — | — | EP | disclosed |
| EP-2326627-A1 | SUBSTITUTED PYRIDINE AND PYRIMIDINE DERIVATIVES AND THEIR USE IN TREATING VIRAL INFECTIONS | Schering Corporation (US) | 2011-06-01 | — | — | EP | disclosed |
| EP-2326628-A1 | AZO-SUBSTITUTED PYRIDINE AND PYRIMIDINE DERIVATIVES AND THEIR USE IN TREATING VIRAL INFECTIONS | Schering Corporation (US) | 2011-06-01 | — | — | EP | disclosed |
| US-20110104110-A1 | SUBSTITUTED INDOLE DERIVATIVES AND METHODS OF USE THEREOF | SHERING CORPORATION | 2011-05-05 | — | — | US | disclosed |
| US-20110104109-A1 | TETRACYCLIC INDOLE DERIVATIVES AND THEIR USE FOR TREATING OR PREVENTING VIRAL INFECTIONS | MERCK SHARP & DOHME CORP. | 2011-05-05 | — | — | US | disclosed |
| CN-102031305-A | Recombinant cell containing influenza A specific promoter and application thereof | CHINESE ACAD INST MICROBIOLOGY | 2011-04-27 | — | — | CN | disclosed |
| WO-2011047119-A1 | COMPOUNDS FOR THE TREATMENT OF HEPATITIS C | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-04-21 | — | — | WO | disclosed |
| WO-2011046946-A2 | BIFUNCTIONAL MOLECULES WITH ANTIBODY-RECRUITING AND ENTRY INHIBITORY ACTIVITY AGAINST THE HUMAN IMMUNODEFICIENCY VIRUS | YALE UNIVERSITY (US) | 2011-04-21 | — | — | WO | disclosed |
| EP-2303893-A1 | TRICYCLIC INDOLE DERIVATIVES AND METHODS OF USE THEREOF | Schering Corporation (US) | 2011-04-06 | — | — | EP | disclosed |
| US-7919488-B2 | Therapeutic compounds | PFIZER INC. (US) | 2011-04-05 | — | — | US | disclosed |
| EP-2300433-A1 | HIV INTEGRASE INHIBITORS FROM PYRIDOXINE | Ambrilia Biopharma Inc. (CA) | 2011-03-30 | — | — | EP | disclosed |
| EP-2178513-B1 | TABLETED COMPOSITIONS CONTAINING ATAZANAVIR | BRISTOL MYERS SQUIBB CO (US) | 2011-03-30 | — | — | EP | disclosed |
| EP-2178511-B1 | TABLETED COMPOSITIONS CONTAINING ATAZANAVIR | BRISTOL MYERS SQUIBB CO (US) | 2011-03-02 | — | — | EP | disclosed |
| US-7888375-B2 | Pyridinone diketo acids: inhibitors of HIV replication | THE UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC (US) | 2011-02-15 | — | — | US | disclosed |
| US-20110033417-A1 | 2,3-SUBSTITUTED INDOLE DERIVATIVES FOR TREATING VIRAL INFECTIONS | MERCK SHARP & DOHME CORP. | 2011-02-10 | — | — | US | disclosed |
| US-20110028385-A1 | Combination of Immunomodulator and Anti-Pathogenic Agent | NUNES ISEU DA SILVA | 2011-02-03 | — | — | US | disclosed |
| US-7868026-B2 | Therapeutic compounds | PFIZER INC. (US) | 2011-01-11 | — | — | US | disclosed |
| US-20100322901-A1 | 5, 6-RING ANNULATED INDOLE DERIVATIVES AND USE THEREOF | SCHERING CORPORATION | 2010-12-23 | — | — | US | disclosed |
| EP-2259799-A1 | COMBINATION OF IMMUNOMODULATOR AND ANTI-PATHOGENIC AGENT | Nunes, Iseu Da Silva (BR) | 2010-12-15 | — | — | EP | disclosed |
| WO-2010138790-A1 | ANTIVIRAL COMPOUNDS COMPOSED OF THREE ALIGNED ARYL MOIETIES TO TREAT DISEASES SUCH AS HEPATITIS C | SCHERING CORPORATION (US) | 2010-12-02 | — | — | WO | disclosed |
| WO-2010138791-A1 | ANTIVIRAL COMPOUNDS COMPOSED OF THREE LINKED ARYL MOIETIES TO TREAT DISEASES SUCH AS HEPATITIS C | SCHERING CORPORATION (US) | 2010-12-02 | — | — | WO | disclosed |
| US-20100291034-A1 | COMBINATIONS OF HCV PROTEASE INHIBITOR(S) AND CYP3A4 INHIBITOR(S), AND METHODS OF TREATMENT RELATED THERETO | SCHERING CORPORATION (US) | 2010-11-18 | — | — | US | disclosed |
| WO-2010132538-A1 | FUSED TRICYCLIC ARYL COMPOUNDS USEFUL FOR THE TREATMENT OF VIRAL DISEASES | SCHERING CORPORATION (US) | 2010-11-18 | — | — | WO | disclosed |
| WO-2010120759-A1 | INTERFERON-ALFA SENSITIVITY BIOMARKERS | SCHERING CORPORATION (US) | 2010-10-21 | — | — | WO | disclosed |
| US-20100260711-A1 | 3-AMINOSULFONYL SUBSTITUTED INDOLE DERIVATIVES AND METHODS OF USE THEREOF | SCHERING CORPORATION (US) | 2010-10-14 | — | — | US | disclosed |
| US-20100239527-A1 | 2,3-SUBSTITUTED AZAINDOLE DERIVATIVES FOR TREATING VIRAL INFECTIONS | SCHERING CORPORATION (US) | 2010-09-23 | — | — | US | disclosed |
| CN-101842374-A | 2, 3-substituted azaindole derivatives for the treatment of viral infections | SCHERING CORP | 2010-09-22 | — | — | CN | disclosed |
| CN-101842353-A | 2, 3-substituted indole derivatives for treating viral infections | SCHERING CORP | 2010-09-22 | — | — | CN | disclosed |
| CN-101842376-A | Tetracyclic indole derivatives and being used for the treatment of or prophylaxis of viral infections | SCHERING CORP | 2010-09-22 | — | — | CN | disclosed |
| EP-2222660-A1 | 3-HETEROCYCLIC SUBSTITUTED INDOLE DERIVATIVES AND METHODS OF USE THEREOF | Schering Corporation (US) | 2010-09-01 | — | — | EP | disclosed |
| EP-2222672-A1 | 3-AMINOSULFONYL SUBSTITUTED INDOLE DERIVATIVES AND METHODS OF USE THEREOF | Schering Corporation (US) | 2010-09-01 | — | — | EP | disclosed |
| CN-101821252-A | The indole derivatives and the using method thereof that replace | CHERING CORP | 2010-09-01 | — | — | CN | disclosed |
| CN-101801348-A | tableted compositions containing atazanavir | BRISTOL MYERS SQUIBB CO | 2010-08-11 | — | — | CN | disclosed |
| US-7772178-B2 | Pharmaceutical formulations and methods of treatment using the same | SCHERING CORPORATION (US) | 2010-08-10 | — | — | US | disclosed |
| US-20100196319-A1 | 4, 5-RING ANNULATED INDOLE DERIVATIVES FOR TREATING OR PREVENTING OF HCV AND RELATED VIRAL INFECTIONS | SCHERING CORPORATION (US) | 2010-08-05 | — | — | US | disclosed |
| CN-101795674-A | Tableted compositions containing atazanavir | BRISTOL MYERS SQUIBB CO | 2010-08-04 | — | — | CN | disclosed |
| EP-1732604-B1 | METHODS OF TREATING HIV INFECTION | BRISTOL MYERS SQUIBB CO (US) | 2010-07-21 | — | — | EP | disclosed |
| CN-101212970-B | Combination of HCV protease inhibitors with a surfactant | SCHERING CORP | 2010-07-21 | — | — | CN | disclosed |
| EP-1751161-B1 | DIAZAINDOLE-DICARBONYL-PIPERAZINYL ANTIVIRAL AGENTS | BRISTOL MYERS SQUIBB CO (US) | 2010-07-14 | — | — | EP | disclosed |
| EP-2024355-B1 | ALKENE PIPERIDINE DERIVATIVES AS ANTIVIRAL AGENTS | BRISTOL MYERS SQUIBB CO (US) | 2010-07-14 | — | — | EP | disclosed |
| CN-101778624-A | Compressed tablet composition containing atazanavir | BRISTOL MYERS SQUIBB CO | 2010-07-14 | — | — | CN | disclosed |
| CN-101778625-A | Compressed tablet composition containing atazanavir | BRISTOL MYERS SQUIBB CO | 2010-07-14 | — | — | CN | disclosed |
| US-20100172866-A1 | Combination Therapy for the Treatment of HCV Infection | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-07-08 | — | — | US | disclosed |
| EP-2197884-A2 | TETRACYCLIC INDOLE DERIVATIVES AND THEIR USE FOR TREATING OR PREVENTING VIRAL INFECTIONS | SCHERING CORPORATION (US) | 2010-06-23 | — | — | EP | disclosed |
| EP-2197842-A1 | 2, 3-SUBSTITUTED INDOLE DERIVATIVES FOR TREATING VIRAL INFECTIONS | SCHERING CORPORATION (US) | 2010-06-23 | — | — | EP | disclosed |
| EP-2195317-A1 | 2,3-SUBSTITUTED AZAINDOLE DERIVATIVES FOR TREATING VIRAL INFECTIONS | SCHERING CORPORATION (US) | 2010-06-16 | — | — | EP | disclosed |
| US-20100137283-A1 | INHIBITORS OF THE HIV INTEGRASE ENZYME | PFIZER INC | 2010-06-03 | — | — | US | disclosed |
| US-20100098661-A1 | 4,5-RING ANNULATED INDOLE DERIVATIVES FOR TREATING OR PREVENTING OF HCV AND RELATED VIRAL INFECTIONS | SCHERING CORPORATION | 2010-04-22 | — | — | US | disclosed |
| US-20100092427-A1 | Pyridinone Diketo Acids: Inhibitors of HIV Replication in Combination Therapy | THE UNIVERSITY OF GEORGIA RESEARCH FOUNDATION (US) | 2010-04-15 | — | — | US | disclosed |
| EP-2170357-A1 | DELIVERY OF MICRO-AND NANOPARTICLES WITH BLOOD PLATELETS | Entegrion, Inc. (US) | 2010-04-07 | — | — | EP | disclosed |
| US-7692014-B2 | Inhibitors of the HIV integrase enzyme | PFIZER, INC. (US) | 2010-04-06 | — | — | US | disclosed |
| US-20100076191-A1 | PROCESS FOR PREPARING TRIAZOLE SUBSTITUTED AZAINDOLEOXOACETIC PIPERAZINE DERIVATIVES AND NOVEL SALT FORMS PRODUCED THEREIN | BRISTOL-MYERS SQUIBB COMPANY | 2010-03-25 | — | — | US | disclosed |
| EP-1948666-B1 | HIV INTEGRASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2010-03-17 | — | — | EP | disclosed |
| EP-1937639-B1 | PYRIDINAMINOSULFONYL SUBSTITUTED BENZAMIDES AS INHIBITORS OF CYTOCHROME P450 3A4 (CYP3A4) | PFIZER PROD INC (US) | 2010-03-03 | — | — | EP | disclosed |
| WO-2010022121-A1 | SUBSTITUTED PYRIDINE AND PYRIMIDINE DERIVATIVES AND THEIR USE IN TREATING VIRAL INFECTIONS | SCHERING CORPORATION (US) | 2010-02-25 | — | — | WO | disclosed |
| WO-2010022128-A1 | ETHENYL-SUBSTITUTED PYRIDINE AND PYRIMIDINE DERIVATIVES AND THEIR USE IN TREATING VIRAL INFECTIONS | SCHERING CORPORATION (US) | 2010-02-25 | — | — | WO | disclosed |
| WO-2010022125-A1 | ETHYNYL-SUBSTITUTED PYRIDINE AND PYRIMIDINE DERIVATIVES AND THEIR USE IN TREATING VIRAL INFECTIONS | SCHERING CORPORATION (US) | 2010-02-25 | — | — | WO | disclosed |
| WO-2010022126-A1 | AZO-SUBSTITUTED PYRIDINE AND PYRIMIDINE DERIVATIVES AND THEIR USE IN TREATING VIRAL INFECTIONS | SCHERING CORPORATION (US) | 2010-02-25 | — | — | WO | disclosed |
| CN-101631773-A | 4 of treatment or prevention HCV and related viral infections, the 5-ring annulated indole derivatives | SCHERING CORP | 2010-01-20 | — | — | CN | disclosed |
| EP-2142215-A2 | COMBINATION THERAPY FOR THE TREATMENT OF HCV INFECTION | Vertex Pharmceuticals Incorporated (US) | 2010-01-13 | — | — | EP | disclosed |
| CN-101611002-A | 4, 5-cyclized indole derivatives for the treatment or prevention of HCV and related viral infections | SCHERING CORP (US) | 2009-12-23 | — | — | CN | disclosed |
| WO-2009152200-A1 | TRICYCLIC INDOLE DERIVATIVES AND METHODS OF USE THEREOF | SCHERING CORPORATION (US) | 2009-12-17 | — | — | WO | disclosed |
| WO-2009146555-A1 | HIV INTEGRASE INHIBITORS FROM PYRIDOXINE | AMBRILIA BIOPHARMA INC. (CA) | 2009-12-10 | — | — | WO | disclosed |
| EP-1745052-B9 | HIV INTEGRASE INHIBITORS: CYCLIC PYRIMIDINONE COMPOUNDS | BRISTOL MYERS SQUIBB CO (US) | 2009-10-28 | — | — | EP | disclosed |
| EP-1381366-B9 | INDOLE, AZAINDOLE AND RELATED HETEROCYCLIC AMIDOPIPERAZINE DERIVATIVES | BRISTOL MYERS SQUIBB CO (US) | 2009-10-21 | — | — | EP | disclosed |
| US-20090220457-A1 | COMBINATIONS COMPRISING HCV PROTEASE INHIBITOR(S) AND HCV IRES INHIBITOR(S), AND METHODS OF TREATMENT RELATED THERETO | PTC THERAPEUTICS, INC. | 2009-09-03 | — | — | US | disclosed |
| CN-101511812-A | Pyrazole derivatives as cytochrome P450 inhibitors | PFIZER PROD INC (US) | 2009-08-19 | — | — | CN | disclosed |
| WO-2009097670-A1 | COMBINATION OF IMMUNOMODULATOR AND ANTI-PATHOGENIC AGENT | NUNES ISEU DA SILVA (BR) | 2009-08-13 | — | — | WO | disclosed |
| US-7569573-B2 | Diketo acids with nucleobase scaffolds: anti-HIV replication inhibitors targeted at HIV integrase | THE UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 2009-08-04 | — | — | US | disclosed |
| EP-2081922-A2 | 5,6-RING ANNULATED INDOLE DERIVATIVES AND USE THEREOF | SCHERING CORPORATION (US) | 2009-07-29 | — | — | EP | disclosed |
| US-20090170846-A1 | INHIBITORS OF THE HIV INTEGRASE ENZYME | PFIZER INC | 2009-07-02 | — | — | US | disclosed |
| EP-2064181-A1 | 4, 5-RING ANNULATED INDOLE DERIVATIVES FOR TREATING OR PREVENTING OF HCV AND RELATED VIRAL INFECTIONS | SCHERING CORPORATION (US) | 2009-06-03 | — | — | EP | disclosed |
| EP-2064180-A1 | 4,5-RING ANNULATED INDOLE DERIVATIVES FOR TREATING OR PREVENTING OF HCV AND RELATED VIRAL INFECTIONS | SCHERING CORPORATION (US) | 2009-06-03 | — | — | EP | disclosed |
| WO-2009064852-A1 | 3-AMINOSULFONYL SUBSTITUTED INDOLE DERIVATIVES AND METHODS OF USE THEREOF | SCHERING CORPORATION (US) | 2009-05-22 | — | — | WO | disclosed |
| WO-2009064848-A1 | 3-HETEROCYCLIC SUBSTITUTED INDOLE DERIVATIVES AND METHODS OF USE THEREOF | SCHERING CORPORATION (US) | 2009-05-22 | — | — | WO | disclosed |
| EP-1326865-B1 | AZA- AND POLYAZA-NAPHTHALENYL CARBOXAMIDES USEFUL AS HIV INTEGRASE INHIBITORS | MERCK & CO INC (US) | 2009-05-06 | — | — | EP | disclosed |
| EP-1381366-B1 | INDOLE, AZAINDOLE AND RELATED HETEROCYCLIC AMIDOPIPERAZINE DERIVATIVES | BRISTOL MYERS SQUIBB CO (US) | 2009-04-22 | — | — | EP | disclosed |
| EP-2046774-A1 | PYRAZOLE DERIVATIVES AS CYTOCHROME P450 INHIBITORS | Pfizer Products Inc. (US) | 2009-04-15 | — | — | EP | disclosed |
| EP-2046328-A2 | PYRIDINONE DIKETO ACIDS: INHIBITORS OF HIV REPLICATION IN COMBINATION THERAPY | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 2009-04-15 | — | — | EP | disclosed |
| WO-2009032124-A1 | SUBSTITUTED INDOLE DERIVATIVES AND METHODS OF USE THEREOF | SCHERING CORPORATION (US) | 2009-03-12 | — | — | WO | disclosed |
| WO-2009032116-A1 | 2, 3-SUBSTITUTED INDOLE DERIVATIVES FOR TREATING VIRAL INFECTIONS | SCHERING CORPORATION (US) | 2009-03-12 | — | — | WO | disclosed |
| WO-2009032123-A2 | TETRACYCLIC INDOLE DERIVATIVES AND THEIR USE FOR TREATING OR PREVENTING VIRAL INFECTIONS | SCHERING CORPORATION (US) | 2009-03-12 | — | — | WO | disclosed |
| WO-2009032125-A1 | 2,3-SUBSTITUTED AZAINDOLE DERIVATIVES FOR TREATING VIRAL INFECTIONS | SCHERING CORPORATION (US) | 2009-03-12 | — | — | WO | disclosed |
| US-7468375-B2 | Inhibitors of the HIV integrase enzyme | PFIZER INC. (US) | 2008-12-23 | — | — | US | disclosed |
| EP-1998765-A2 | PHARMACEUTICAL COMBINATIONS OF HCV-PROTEASE AND -IRES INHIBITORS | SCHERING CORPORATION (US) | 2008-12-10 | — | — | EP | disclosed |
| CN-101317577-A | Medicament for preventing and controlling plant virus disease | TAI AN XIANHE AGRICULTURAL TEC (CN) | 2008-12-10 | — | — | CN | disclosed |
| EP-1998759-A2 | COMBINATIONS OF HCV PROTEASE INHIBITOR(S) AND CYP3A4 INHIBITOR(S), AND METHODS OF TREATMENT RELATED THERETO | SCHERING CORPORATION (US) | 2008-12-10 | — | — | EP | disclosed |
| WO-2008143769-A1 | DELIVERY OF MICRO-AND NANOPARTICLES WITH BLOOD PLATELETS | ENTEGRION, INC. (US) | 2008-11-27 | — | — | WO | disclosed |
| WO-2008136815-A2 | 5, 6-RING ANNULATED INDOLE DERIVATIVES AND USE THEREOF | SCHERING CORPORATION (US) | 2008-11-13 | — | — | WO | disclosed |
| WO-2008137126-A2 | COMBINATION THERAPY FOR THE TREATMENT OF HCV INFECTION | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2008-11-13 | — | — | WO | disclosed |
| EP-1749011-B1 | BICYCLIC HETEROCYCLES AS HIV INTEGRASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2008-10-29 | — | — | EP | disclosed |
| EP-1981524-A2 | COMBINATIONS COMPRISING HCV PROTEASE INHIBITOR(S) AND HCV POLYMERASE INHIBITOR(S), AND METHODS OF TREATMENT RELATED THERETO | SCHERING CORPORATION (US) | 2008-10-22 | — | — | EP | disclosed |
| EP-1496836-B1 | N-(SUBSTITUTED BENZYL)-8-HYDROXY-1,6-NAPHTHYRIDINE-7- CARBOXAMIDES USEFUL AS HIV INTEGRASE INHIBITORS | MERCK & CO INC (US) | 2008-09-24 | — | — | EP | disclosed |
| EP-1745052-B1 | HIV INTEGRASE INHIBITORS: CYCLIC PYRIMIDINONE COMPOUNDS | BRISTOL MYERS SQUIBB CO (US) | 2008-08-20 | — | — | EP | disclosed |
| EP-1539714-B1 | 8-HYDROXY-1-OXO-TETRAHYDROPYRROLOPYRAZINE COMPOUNDS USEFUL AS HIV INTEGRASE INHIBITORS | MERCK & CO INC (US) | 2008-08-13 | — | — | EP | disclosed |
| EP-1474135-B9 | INDOLE, AZAINDOLE AND RELATED HETEROCYCLIC PYRROLIDINE DERIVATIVES | BRISTOL MYERS SQUIBB CO (US) | 2008-08-06 | — | — | EP | disclosed |
| EP-1943249-A1 | INHIBITORS OF THE HIV INTEGRASE ENZYME | Pfizer Products Incorporated (US) | 2008-07-16 | — | — | EP | disclosed |
| WO-2008082484-A1 | 4,5-RING ANNULATED INDOLE DERIVATIVES FOR TREATING OR PREVENTING OF HCV AND RELATED VIRAL INFECTIONS | SCHERING CORPORATION (US) | 2008-07-10 | — | — | WO | disclosed |
| WO-2008082488-A1 | 4, 5-RING ANNULATED INDOLE DERIVATIVES FOR TREATING OR PREVENTING OF HCV AND RELATED VIRAL INFECTIONS | SCHERING CORPORATION (US) | 2008-07-10 | — | — | WO | disclosed |
| CN-101212970-A | Combination of HCV protease inhibitors with a surfactant | SCHERING CORP (US) | 2008-07-02 | — | — | CN | disclosed |
| EP-1937639-A2 | PYRIDINAMINOSULFONYL SUBSTITUTED BENZAMIDES AS INHIBITORS OF CYTOCHROME P450 3A4 (CYP3A4) | Pfizer Products Incorporated (US) | 2008-07-02 | — | — | EP | disclosed |
| EP-1934220-A1 | INHIBITORS OF THE HIV INTEGRASE ENZYME | Pfizer Products Incorporated (US) | 2008-06-25 | — | — | EP | disclosed |
| EP-1919478-A2 | COMBINATION OF HCV PROTEASE INHIBITORS WITH A SURFACTANT | SCHERING CORPORATION (US) | 2008-05-14 | — | — | EP | disclosed |
| EP-1898941-A2 | CONTROLLED-RELEASE FORMULATION USEFUL FOR TREATING DISORDERS ASSOCIATED WITH HEPATITIS C VIRUS | SCHERING CORPORATION (US) | 2008-03-19 | — | — | EP | disclosed |
| EP-1891089-A2 | HCV PROTEASE INHIBITORS IN COMBINATION WITH FOOD | SCHERING CORPORATION (US) | 2008-02-27 | — | — | EP | disclosed |
| US-20080020010-A1 | Pyridinone diketo acids: inhibitors of HIV replication | THE UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 2008-01-24 | — | — | US | disclosed |
| US-20080021011-A1 | THERAPEUTIC COMPOUNDS | PFIZER INC | 2008-01-24 | — | — | US | disclosed |
| WO-2008010953-A2 | PYRIDINONE DIKETO ACIDS: INHIBITORS OF HIV REPLICATION IN COMBINATION THERAPY | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 2008-01-24 | — | — | WO | disclosed |
| EP-1725569-B1 | PRODRUGS OF PIPERAZINE AND SUBSTITUTED PIPERIDINE ANTIVIRAL AGENTS | BRISTOL MYERS SQUIBB CO (US) | 2008-01-23 | — | — | EP | disclosed |
| WO-2008004096-A1 | PYRAZOLE DERIVATIVES AS CYTOCHROME P450 INHIBITORS | PFIZER PRODUCTS INC. (US) | 2008-01-10 | — | — | WO | disclosed |
| WO-2008004100-A2 | THERAPEUTIC COMPOUNDS | PFIZER PRODUCTS INC. (US) | 2008-01-10 | — | — | WO | disclosed |
| EP-1873155-A1 | Inhibitors of the HIV integrase enzyme | PFIZER INC. (US) | 2008-01-02 | — | — | EP | disclosed |
| US-20070287664-A1 | Combinations of HCV protease inhibitor(s) and CYP3A4 inhibitor(s), and methods of treatment related thereto | SCHERING CORPORATION | 2007-12-13 | — | — | US | disclosed |
| WO-2007139585-A1 | CONTROLLED-RELEASE FORMULATION | SCHERING CORPORATION (US) | 2007-12-06 | — | — | WO | disclosed |
| EP-1499319-B1 | BICYCLO 4.4.0 ANTIVIRAL DERIVATIVES | BRISTOL MYERS SQUIBB CO (US) | 2007-12-05 | — | — | EP | disclosed |
| US-20070274951-A1 | Combinations comprising HCV protease inhibitor(s) and HCV polymerase inhibitor(s), and methods of treatment related thereto | SCHERING CORPORATION | 2007-11-29 | — | — | US | disclosed |
| EP-1474135-B1 | INDOLE, AZAINDOLE AND RELATED HETEROCYCLIC PYRROLIDINE DERIVATIVES | BRISTOL MYERS SQUIBB CO (US) | 2007-11-21 | — | — | EP | disclosed |
| US-20070259823-A1 | Diketo acids with nucleobase scaffolds: anti-HIV replication inhibitors targeted at HIV integrase | THE UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC (US) | 2007-11-08 | — | — | US | disclosed |
| EP-1848697-A2 | DIKETO ACIDS WITH NUCLEOBASE SCAFFOLDS: ANTI-HIV REPLICATION INHIBITORS TARGETED AT HIV INTEGRASE | THE UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 2007-10-31 | — | — | EP | disclosed |
| US-20070237818-A1 | Controlled-release formulation of HCV protease inhibitor and methods using the same | SCHERING CORPORATION | 2007-10-11 | — | — | US | disclosed |
| WO-2007111866-A2 | COMBINATIONS OF HCV PROTEASE INHIBITOR(S) AND CYP3A4 INHIBITOR(S), AND METHODS OF TREATMENT RELATED THERETO | SCHERING CORPORATION (US) | 2007-10-04 | — | — | WO | disclosed |
| US-20070232644-A1 | 1-(2,4-difluorobenzyl)-N-hydroxy-3-{[3-(methylsulfonyl)pyrrolidin-1-yl]methyl}-1H-pyrrolo[2,3-c]pyridine-5-carboxamide;acquired immunodeficiency syndrome (\"AIDS\"), and AIDS related complex (\"ARC\") | PFIZER INC. | 2007-10-04 | — | — | US | disclosed |
| US-20070232527-A1 | Medicaments and methods combining a HCV protease inhibitor and an AKR competitor | SCHERING CORPORATION | 2007-10-04 | — | — | US | disclosed |
| EP-1751157-B1 | INHIBITORS OF THE HIV INTEGRASE ENZYME | PFIZER (US) | 2007-10-03 | — | — | EP | disclosed |
| WO-2007106450-A2 | DIKETO ACIDS WITH NUCLEOBASE SCAFFOLDS: ANTI-HIV REPLICATION INHIBITORS TARGETED AT HIV INTEGRASE IN COMBINATION THERAPY | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 2007-09-20 | — | — | WO | disclosed |
| WO-2007106317-A2 | PHARMACEUTICAL COMBINATIONS OF HCV-PROTEASE AND -IRES INHIBITORS | SCHERING CORPORATION (US) | 2007-09-20 | — | — | WO | disclosed |
| US-20070207949-A1 | Medicaments and methods combining a HCV protease inhibitor and an AKR competitor | SCHERING CORPORATION | 2007-09-06 | — | — | US | disclosed |
| EP-1467970-B1 | HYDROXYNAPHTHYRIDINONE CARBOXAMIDES USEFUL AS HIV INTEGRASE INHIBITORS | MERCK & CO INC (US) | 2007-08-22 | — | — | EP | disclosed |
| WO-2007092616-A2 | COMBINATIONS COMPRISING HCV PROTEASE INHIBITOR(S) AND HCV POLYMERASE INHIBITOR(S), AND METHODS OF TREATMENT RELATED THERETO | SCHERING CORPORATION (US) | 2007-08-16 | — | — | WO | disclosed |
| US-20070167497-A1 | Therapeutic Compounds | PFIZER INC | 2007-07-19 | — | — | US | disclosed |
| CN-1326536-C | Pharmaceutical composition for treating and preventing respiratory tract viral infection, its preparation process and application | SHI HONGBO (CN) | 2007-07-18 | — | — | CN | disclosed |
| EP-1802619-A1 | INHIBITORS OF THE HIV INTEGRASE ENZYME | Pfizer, Inc. (US) | 2007-07-04 | — | — | EP | disclosed |
| CN-1984917-A | HIV integrase inhibitors: cyclic pyrimidinone compounds | BRISTOL MYERS SQUIBB CO (US) | 2007-06-20 | — | — | CN | disclosed |
| US-20070099915-A1 | INHIBITORS OF THE HIV INTEGRASE ENZYME | PFIZER INC. | 2007-05-03 | — | — | US | disclosed |
| WO-2007042883-A1 | INHIBITORS OF THE HIV INTEGRASE ENZYME | PFIZER PRODUCTS INC. (US) | 2007-04-19 | — | — | WO | disclosed |
| WO-2007039802-A1 | INHIBITORS OF THE HIV INTEGRASE ENZYME | PFIZER PRODUCTS INC. (US) | 2007-04-12 | — | — | WO | disclosed |
| WO-2007034312-A2 | PYRIDINAMINOSULFONYL SUBSTITUTED BENZAMIDES AS INHIBITORS OF CYTOCHROME P450 3A4 (CYP3A4) | PFIZER PRODUCTS INC. (US) | 2007-03-29 | — | — | WO | disclosed |
| CN-1938017-A | Therapeutic combinations | AGOURON PHARMA (US) | 2007-03-28 | — | — | CN | disclosed |
| US-20070066664-A1 | HIV PROTEASE INHIBITORS, COMPOSITIONS CONTAINING THE SAME, THEIR PHARMACEUTICAL USES, MATERIALS FOR THEIR SYNTHESIS | PFIZER INC | 2007-03-22 | — | — | US | disclosed |
| EP-1441734-B1 | DIHYDROXYPYRIMIDINE CARBOXAMIDE INHIBITORS OF HIV INTEGRASE | ANGELETTI P IST RICHERCHE BIO (IT) | 2007-02-28 | — | — | EP | disclosed |
| EP-1756103-A2 | PYRROLOPYRIDINE DERIVATIVES AND THEIR USE AS HIV-INTEGRASE INHIBITORS | Pfizer, Inc. (US) | 2007-02-28 | — | — | EP | disclosed |
| EP-1751157-A1 | INHIBITORS OF THE HIV INTEGRASE ENZYME | PFIZER INC. (US) | 2007-02-14 | — | — | EP | disclosed |
| CN-1906199-A | Diazaindole-dicarbonyl-piperazinyl antiviral agents | BRISTOL MYERS SQUIBB CO (US) | 2007-01-31 | — | — | CN | disclosed |
| US-7169932-B2 | HIV protease inhibitors, compositions containing the same, their pharmaceutical uses, material for their synthesis | PFIZER INC. (US) | 2007-01-30 | — | — | US | disclosed |
| US-20070021351-A1 | Liver/plasma concentration ratio for dosing hepatitis C virus protease inhibitor | SCHERING CORPORATION | 2007-01-25 | — | — | US | disclosed |
| US-20070010431-A1 | Pharmaceutical formulations and methods of treatment using the same | SCHERING CORPORATION | 2007-01-11 | — | — | US | disclosed |
| US-20070004635-A1 | Method of treating interferon non-responders using HCV protease inhibitor | SCHERING CORPORATION | 2007-01-04 | — | — | US | disclosed |
| US-20060287248-A1 | Asymmetric dosing methods | SCHERING CORPORATION | 2006-12-21 | — | — | US | disclosed |
| US-20060281688-A1 | Administration of HCV protease inhibitors in combination with food to improve bioavailability | SCHERING CORPORATION | 2006-12-14 | — | — | US | disclosed |
| US-20060281689-A1 | Method for modulating activity of HCV protease through use of a novel HCV protease inhibitor to reduce duration of treatment period | SCHERING CORPORATION | 2006-12-14 | — | — | US | disclosed |
| US-20060275366-A1 | Controlled-release formulation | SCHERING CORPORATION | 2006-12-07 | — | — | US | disclosed |
| US-20060276404-A1 | Medicaments and methods combining a HCV protease inhibitor and an AKR competitor | SCHERING CORPORATION | 2006-12-07 | — | — | US | disclosed |
| US-20060276407-A1 | Methods of treating hepatitis C virus | SCHERING CORPORATION | 2006-12-07 | — | — | US | disclosed |
| WO-2006130686-A2 | HCV PROTEASE INHIBITORS IN COMBINATION WITH FOOD | SCHERING CORPORATION (US) | 2006-12-07 | — | — | WO | disclosed |
| WO-2006130607-A2 | CONTROLLED-RELEASE FORMULATION USEFUL FOR TREATING DISORDERS ASSOCIATED WITH HEPATITIS C VIRUS | SCHERING CORPORATION (US) | 2006-12-07 | — | — | WO | disclosed |
| WO-2006130666-A2 | MEDICAMENTS AND METHODS COMBINING A HCV PROTEASE INHIBITOR AND AN AKR COMPETITOR | SCHERING CORPORATION (US) | 2006-12-07 | — | — | WO | disclosed |
| WO-2006130687-A2 | LIVER/PLASMA CONCENTRATION RATIO FOR DOSING HEPATITIS C VIRUS PROTEASE INHIBITOR | SCHERING CORPORATION (US) | 2006-12-07 | — | — | WO | disclosed |
| WO-2006130553-A2 | HCV PROTEASE INHIBITORS | SCHERING CORPORATION (US) | 2006-12-07 | — | — | WO | disclosed |
| WO-2006130552-A2 | METHODS OF TREATING HEPATITIS C VIRUS | SCHERING CORPORATION (US) | 2006-12-07 | — | — | WO | disclosed |
| US-20060276405-A1 | Methods for treating hepatitis C | SCHERING CORPORATION | 2006-12-07 | — | — | US | disclosed |
| US-20060276406-A1 | Methods of treating hepatitis C virus | SCHERING CORPORATION | 2006-12-07 | — | — | US | disclosed |
| WO-2006130688-A2 | COMPOUNDS FOR INHIBITING CATHEPSIN ACTIVITY | SCHERING CORPORATION (US) | 2006-12-07 | — | — | WO | disclosed |
| WO-2006130628-A2 | COMBINATION OF HCV PROTEASE INHIBITORS WITH A SURFACTANT | SCHERING CORPORATION (US) | 2006-12-07 | — | — | WO | disclosed |
| WO-2006130626-A2 | METHOD FOR MODULATING ACTIVITY OF HCV PROTEASE THROUGH USE OF A NOVEL HCV PROTEASE INHIBITOR TO REDUCE DURATION OF TREATMENT PERIOD | SCHERING CORPORATION (US) | 2006-12-07 | — | — | WO | disclosed |
| WO-2006130554-A2 | METHODS OF TREATING HEPATITIS C VIRUS | SCHERING CORPORATION (US) | 2006-12-07 | — | — | WO | disclosed |
| WO-2006130627-A2 | METHODS FOR TREATING HEPATITIS C | SCHERING CORPORATION (US) | 2006-12-07 | — | — | WO | disclosed |
| US-7138408-B2 | HIV integrase inhibitors, pharmaceutical compositions and methods for their use | AGOURON PHARMACEUTICALS, INC. (US) | 2006-11-21 | — | — | US | disclosed |
| EP-1713470-A1 | THERAPEUTIC COMBINATIONS | Pfizer, Inc. (US) | 2006-10-25 | — | — | EP | disclosed |
| EP-1713478-A1 | COMPOSITIONS COMPRISING HIV PROTEASE INHIBITOR AND CYTOCHROME P450 ENZYME ACTIVITY INHIBITOR | PFIZER INC. (US) | 2006-10-25 | — | — | EP | disclosed |
| CN-1850146-A | Use of extract of Fructus Pithecellobii clypeoriae conrmon Apes Ear-ring Fruit | LAITAI PHARMACY CO LTD GUANGZH (CN) | 2006-10-25 | — | — | CN | disclosed |
| WO-2006097848-A1 | HIV-1 VIRION MATURATION INHIBITORS, COMPOSITIONS AND TREATMENTS USING THE SAME | PFIZER INC. (US) | 2006-09-21 | — | — | WO | disclosed |
| US-7094909-B2 | Reacting an amide compound containing hydroxy and a carboxyl group and having benzene ring, with a halogenated alkyl aminocarbonyl-pyrrolidine with 2-fluoro groups substituted at the ring carbon, by amindation of amine and carboxyl group | AGOURON PHARMACEUTICALS, INC. (US) | 2006-08-22 | — | — | US | disclosed |
| WO-2006083553-A2 | DIKETO ACIDS WITH NUCLEOBASE SCAFFOLDS: ANTI-HIV REPLICATION INHIBITORS TARGETED AT HIV INTEGRASE | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 2006-08-10 | — | — | WO | disclosed |
| US-20060122211-A1 | HIV integrase inhibitors, pharmaceutical compositions and methods for their use | AGOURON PHARMACEUTICALS, INC. | 2006-06-08 | — | — | US | disclosed |
| WO-2006027694-A1 | INHIBITORS OF THE HIV INTEGRASE ENZYME | PFIZER INC. (US) | 2006-03-16 | — | — | WO | disclosed |
| EP-1441735-B1 | N-SUBSTITUTED HYDROXYPYRIMIDINONE CARBOXAMIDE INHIBITORS OF HIV INTEGRASE | ANGELETTI P IST RICHERCHE BIO (IT) | 2006-02-22 | — | — | EP | disclosed |
| US-7001912-B2 | HIV-integrase inhibitors, pharmaceutical compositions, and methods for their use | AGOURON PHARMACEUTICALS, INC. (US) | 2006-02-21 | — | — | US | disclosed |
| US-20060035932-A1 | N-aryl piperidine compounds | PROPHARMACON, INC. (US) | 2006-02-16 | — | — | US | disclosed |
| US-20060024271-A1 | Treatments for viral infections using IFN cytokines and ribavirin, alone or in combination | AFG BIOSOLUTIONS, INC. | 2006-02-02 | — | — | US | disclosed |
| EP-1257276-B1 | ANTIVIRAL AZAINDOLE DERIVATIVES | BRISTOL MYERS SQUIBB CO (US) | 2005-12-28 | — | — | EP | disclosed |
| WO-2005120503-A2 | N-ARYL PIPERIDINE COMPOUNDS FOR INHIBITING HIV INFECTION | PROPHARMACON, INC. (US) | 2005-12-22 | — | — | WO | disclosed |
| US-20050277662-A1 | Inhibitors of the HIV integrase enzyme | AGOURON PHARMACEUTICALS, INC | 2005-12-15 | — | — | US | disclosed |
| US-20050277661-A1 | Inhibitors of the HIV integrase enzyme | AGOURON PHARMACEUTICALS, INC. | 2005-12-15 | — | — | US | disclosed |
| WO-2005103051-A1 | INHIBITORS OF THE HIV INTEGRASE ENZYME | PFIZER INC. (US) | 2005-11-03 | — | — | WO | disclosed |
| WO-2005103003-A2 | PYRROLOPYRIDINE DERIVATIVES AND THEIR USE AS HIV-INTEGRASE INHIBITORS | PFIZER INC. (US) | 2005-11-03 | — | — | WO | disclosed |
| EP-1590349-A1 | HIV-INTEGRASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND METHODS FOR THEIR USE | PFIZER INC. (US) | 2005-11-02 | — | — | EP | disclosed |
| CN-1688311-A | Compositions and antiviral activity of substituted azaindoloxoacetylpiperazine derivatives | BRISTOL MYERS SQUIBB CO (US) | 2005-10-26 | — | — | CN | disclosed |
| US-6951848-B2 | Functionalized heterocycles as modulators of chemokine receptor function and methods of use therefor | MILLENNIUM PHARMACEUTICALS, INC., (US) | 2005-10-04 | — | — | US | disclosed |
| EP-1299382-B1 | COMPOSITION AND ANTIVIRAL ACTIVITY OF SUBSTITUTED INDOLEOXOACETIC PIPERAZINE DERIVATIVES | BRISTOL MYERS SQUIBB CO (US) | 2005-09-21 | — | — | EP | disclosed |
| WO-2005082362-A1 | THERAPEUTIC COMBINATIONS | PFIZER INC. (US) | 2005-09-09 | — | — | WO | disclosed |
| WO-2005082364-A1 | COMPOSITIONS COMPRISING HIV PROTEASE INHIBITOR AND CYTOCHROME P450 ENZYME ACTIVITY INHIBITOR | PFIZER INC. (US) | 2005-09-09 | — | — | WO | disclosed |
| US-20050171038-A1 | N-allyl-3-{2-hydroxy-3-[(3-hydroxy-2-methylbenzoyl)amino]-4-phenylbutanoyl}-5,5-dimethyl-1,3-thiazolidine-4-carboxamide with HIV enzyme inhibitor | AGOURON PHARMACEUTICALS, INC. | 2005-08-04 | — | — | US | disclosed |
| US-20050171037-A1 | Therapeutic combinations | AGOURON PHARMACEUTICALS, INC. | 2005-08-04 | — | — | US | disclosed |
| US-20050165040-A1 | HIV-integrase inhibitors, pharmaceutical compositions, and methods for their use | AGOURON PHARMACEUTICALS, INC. | 2005-07-28 | — | — | US | disclosed |
| US-20050129772-A1 | Compositions comprising an HIV protease inhibitor | AGOURON PHARMACEUTICALS, INC. | 2005-06-16 | — | — | US | disclosed |
| US-20050124683-A1 | HIV protease inhibitors, compositions containing the same, their pharmaceutical uses and materials for their synthesis | AGOURON PHARMACEUTICALS, INC. | 2005-06-09 | — | — | US | disclosed |
| US-20050075348-A1 | Functionalized heterocycles as modulators of chemokine receptor function and methods of use therefor | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2005-04-07 | — | — | US | disclosed |
| WO-2005026114-A1 | HIV PROTEASE INHIBITORS, COMPOSITIONS CONTAINING THE SAME AND THEIR PHARMACEUTICAL USES | PFIZER INC. (US) | 2005-03-24 | — | — | WO | disclosed |
| EP-1501841-A2 | NON NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | GILEAD SCIENCES, INC. (US) | 2005-02-02 | — | — | EP | disclosed |
| US-20040204591-A1 | HIV protease inhibitors, compositions containing the same, their pharmaceutical uses and materials for their synthesis | AGOURON PHARMACEUTICALS, INC. | 2004-10-14 | — | — | US | disclosed |
| US-20040171842-A1 | HIV protease inhibitors, compositions containing the same, their pharmaceutical uses, material for their synthesis | PFIZER INC | 2004-09-02 | — | — | US | disclosed |
| WO-2004067531-A1 | HIV-INTEGRASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND METHODS FOR THEIR USE | PFIZER INC. (US) | 2004-08-12 | — | — | WO | disclosed |
| EP-1377549-A1 | FUNCTIONALIZED HETEROCYCLES AS MODULATORS OF CHEMOKINE RECEPTOR FUNCTION AND METHODS OF USE THEREFOR | Millennium Pharmaceuticals, Inc. (US) | 2004-01-07 | — | — | EP | disclosed |
| EP-0756449-B1 | METHOD OF ENHANCING WOUND HEALING BY STIMULATING FIBROBLAST AND KERATINOCYTE GROWTH IN VIVO, UTILIZING AMPHIPATHIC PEPTIDES | DEMETER BIOTECH LTD (US) | 2003-11-19 | — | — | EP | disclosed |
| WO-2003091264-A2 | NON NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | GILEAD SCIENCES, INC. (US) | 2003-11-06 | — | — | WO | disclosed |
| EP-0766674-B1 | NEW HIV PROTEASE INHIBITORS | MERCK & CO INC (US) | 2003-10-15 | — | — | EP | disclosed |
| US-20030181436-A1 | Treatment for AIDS, HIV, and other related diseases and compounds for use therewith | SAKALOSKY GEORGE P (US) | 2003-09-25 | — | — | US | disclosed |
| US-6506751-B1 | The compounds are useful in the treatment and prevention of the AIDS virus. Intermediates useful in the preparation of the final products, pharmaceutical compositions containing the final products are also taught. invention is directed to | MILLENNIUM PHARMACEUTICALS, INC. | 2003-01-14 | — | — | US | disclosed |
| EP-0617968-B1 | HIV protease inhibitors in pharmaceutical combinations for the treatment of AIDS | MERCK & CO INC (US) | 2003-01-08 | — | — | EP | disclosed |
| WO-2002072549-A1 | FUNCTIONALIZED HETEROCYCLES AS MODULATORS OF CHEMOKINE RECEPTOR FUNCTION AND METHODS OF USE THEREFOR | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2002-09-19 | — | — | WO | disclosed |
| EP-0734387-B1 | HIV PROTEASE INHIBITORS | MERCK & CO INC (US) | 2002-04-10 | — | — | EP | disclosed |
| US-6316449-B1 | Chemokine receptor antagonists | MILLENNIUM PHARMACEUTICALS, INC. | 2001-11-13 | — | — | US | disclosed |
| EP-1144415-A2 | FUNCTIONALIZED HETEROCYCLES AS CHEMOKINE RECEPTOR MODULATORS | WARNER-LAMBERT COMPANY (US) | 2001-10-17 | — | — | EP | disclosed |
| EP-0643970-B1 | The use of 1-beta-D-ribofuranosyl-1,2,4-triazole-3-carboxamide (Ribavirin) for the preparation of a medicament for the treatment of arboviruses | VIRA TEK INC (US) | 2001-08-16 | — | — | EP | disclosed |
| US-6191110-B1 | PROMOTING WOUND HEALING IN MAMMALS WITH PEPTIDES | DEMEGEN, INC. | 2001-02-20 | — | — | US | disclosed |
| WO-2000042045-A2 | FUNCTIONALIZED HETEROCYCLES AS CHEMOKINE RECEPTOR MODULATORS | WARNER-LAMBERT COMPANY (US) | 2000-07-20 | — | — | WO | disclosed |
| US-6001805-A | Method of enhancing wound healing by stimulating fibroblast and keratinocyte growth in vivo, utilizing amphipathic peptides | DEMEGEN, INC. (US) | 1999-12-14 | — | — | US | disclosed |
| EP-0756449-A4 | METHOD OF ENHANCING WOUND HEALING BY STIMULATING FIBROBLAST AND KERATINOCYTE GROWTH IN VIVO, UTILIZING AMPHIPATHIC PEPTIDES | DEMETER BIOTECH LTD (US) | 1999-09-22 | — | — | EP | disclosed |
| US-5916594-A | RAPIDLY DISSOLVING, ORALLY ADMINISTERABLE, WITH HIGH TAP DENSITY USED TO TREAT HEPATITIS C | SCHERING CORPORATION | 1999-06-29 | — | — | US | disclosed |
| US-5773413-A | ANTITUMOR AGENTS AND ANTICARCINOGENIC AGENTS | DEMETER BIOTECHNOLOGIES, LTD. (US) | 1998-06-30 | — | — | US | disclosed |
| US-5744445-A | CYSTIC FIBROSIS, NEOPLASIAS, BRONCHOGENIC CANCERS, PNEUMONIA, BRONCOPULMONARY MICROBIAL INFECTIONS; DELIVERED BY MOUTH OR AEROSOL TO RESPIRATORY OR GASTROINTESTINAL SYSTEMS | DEMETER BIOTECHNOLOGIES, LTD. (US) | 1998-04-28 | — | — | US | disclosed |
| EP-0707479-A4 | METHOD FOR THE TREATMENT OF NEOPLASTIC DISEASE UTILIZING TIAZOFURIN AND RIBAVIRIN | INDIANA UNIVERSITY FOUNDATION (US) | 1998-04-15 | — | — | EP | disclosed |
| EP-0756449-A1 | METHOD OF ENHANCING WOUND HEALING BY STIMULATING FIBROBLAST AND KERATINOCYTE GROWTH IN VIVO, UTILIZING AMPHIPATHIC PEPTIDES | DEMETER BIOTECHNOLOGIES, LTD. (US) | 1997-02-05 | — | — | EP | disclosed |
| US-5561107-A | Method of enhancing wound healing by stimulating fibroblast and keratinocyte growth in vivo, utilizing amphipathic peptides | DEMETER BIOTECHNOLOGIES, LTD. (US) | 1996-10-01 | — | — | US | disclosed |
| EP-0707479-A1 | METHOD FOR THE TREATMENT OF NEOPLASTIC DISEASE UTILIZING TIAZOFURIN AND RIBAVIRIN | INDIANA UNIVERSITY FOUNDATION (US) | 1996-04-24 | — | — | EP | disclosed |
| WO-1995028832-A1 | METHOD OF ENHANCING WOUND HEALING BY STIMULATING FIBROBLAST AND KERATINOCYTE GROWTH IN VIVO, UTILIZING AMPHIPATHIC PEPTIDES | DEMETER BIOTECHNOLOGIES, LTD. (US) | 1995-11-02 | — | — | WO | disclosed |
| WO-1995027497-A1 | METHOD OF COMBATING MAMMALIAN NEOPLASIA, AND LYTIC PEPTIDES THEREFOR | DEMETER BIOTECHNOLOGIES, LTD. (US) | 1995-10-19 | — | — | WO | disclosed |
| WO-1994028921-A1 | METHOD OF TREATING PULMONARY DISEASE STATES WITH NON-NATURALLY OCCURRING AMPHIPATHIC PEPTIDES | DEMETER BIOTECHNOLOGIES, LTD. (US) | 1994-12-22 | — | — | WO | disclosed |
| WO-1994026281-A1 | METHOD FOR THE TREATMENT OF NEOPLASTIC DISEASE UTILIZING TIAZOFURIN AND RIBAVIRIN | INDIANA UNIVERSITY FOUNDATION (US) | 1994-11-24 | — | — | WO | disclosed |
| WO-1994026749-A1 | HIV PROTEASE INHIBITORS | MERCK & CO., INC. (US) | 1994-11-24 | — | — | WO | disclosed |
| US-4968606-A | FERMENTATION OF MICROORGANISMS WITH OROTIDINE OR OROTIDIC ACID, INORGANIC PHOSPHATE AND 1,2,4-TRIAZOLE-3-CARBOXAMIDE IN WATER | AJINOMOTO CO., INC. (JP) | 1990-11-06 | — | — | US | disclosed |
| US-4840898-A | REACTING A RIBOSE DONOR WITH TRIAZOLE COMPOUND IN PRESENCE OF A BREVIBACTERIUM DERIVED ENZYME | EASTMAN KODAK COMPANY (US) | 1989-06-20 | — | — | US | disclosed |
| US-4840898-A | REACTING A RIBOSE DONOR WITH TRIAZOLE COMPOUND IN PRESENCE OF A BREVIBACTERIUM DERIVED ENZYME | EASTMAN KODAK COMPANY (US) | 1989-06-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (50 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10167298-B2 | Pseudopolymorphs of an HCV NS5A inhibitor and uses thereof | POLI, HAVCR2, EIF2AK2 | LMNA 3760/4885SMN1; SMN2 4461/4885ALDH1A1 3472/4885 |
| US-20120107271-A1 | ETHYNYL-SUBSTITUTED PYRIDINE AND PYRIMIDINE DERIVATIVES AND THEIR USE IN TREATING VIRAL INFECTIONS | CYP2C9, P2RX3, F12 | LMNA 1168/4885SMN1; SMN2 3185/4885ALDH1A1 2333/4885 |
| US-20120316161-A1 | NOVEL ANTIVIRAL COMPOUNDS | MAVS, EIF2AK2, ZC3HAV1 | LMNA 4191/4885SMN1; SMN2 3724/4885ALDH1A1 1275/4885 |
| US-20160122380-A1 | CYCLIC PHOSPHONATE SUBSTITUTED NUCLEOSIDE DERIVATIVES AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES | PNP, SLC29A1, NME2 | LMNA 1745/4885SMN1; SMN2 1939/4885ALDH1A1 2386/4885 |
| US-20110104109-A1 | TETRACYCLIC INDOLE DERIVATIVES AND THEIR USE FOR TREATING OR PREVENTING VIRAL INFECTIONS | IDO1, IDO2, ZC3HAV1 | LMNA 2851/4885SMN1; SMN2 3248/4885ALDH1A1 2482/4885 |
| US-20100196319-A1 | 4, 5-RING ANNULATED INDOLE DERIVATIVES FOR TREATING OR PREVENTING OF HCV AND RELATED VIRAL INFECTIONS | ZC3HAV1, IDO1, ZC3HAV1L | LMNA 4725/4885SMN1; SMN2 4431/4885ALDH1A1 410/4885 |
| US-20110033417-A1 | 2,3-SUBSTITUTED INDOLE DERIVATIVES FOR TREATING VIRAL INFECTIONS | IDO2, IDO1, IRF3 | LMNA 3804/4885SMN1; SMN2 2806/4885ALDH1A1 1792/4885 |
| US-20130280214-A1 | POLYCYCLIC HETEROCYCLE DERIVATIVES AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES | HAVCR2, ZC3HAV1, HCCS | LMNA 2118/4885SMN1; SMN2 3033/4885ALDH1A1 657/4885 |
| US-20140161770-A1 | 2'-CYANO SUBSTITUTED NUCLEOSIDE DERIVATIVES AND METHODS OF USE THEREOF USEFUL FOR THE TREATMENT OF VIRAL DISEASES | HCCS, NSUN2, PNP | LMNA 428/4885SMN1; SMN2 413/4885ALDH1A1 1146/4885 |
| US-20150274739-A1 | 2'-CYANO SUBSTITUTED NUCLEOSIDE DERIVATIVES AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES | NSUN2, RNGTT, NT5C3B | LMNA 1891/4885SMN1; SMN2 808/4885ALDH1A1 2413/4885 |
| US-20050129772-A1 | Compositions comprising an HIV protease inhibitor | DPP4, DNPEP, DPP3 | LMNA 2189/4885SMN1; SMN2 3434/4885ALDH1A1 2691/4885 |
| US-20070004635-A1 | Method of treating interferon non-responders using HCV protease inhibitor | IFNAR1, IFNG, IRF3 | LMNA 1935/4885SMN1; SMN2 3047/4885ALDH1A1 1432/4885 |
| US-20050171038-A1 | N-allyl-3-{2-hydroxy-3-[(3-hydroxy-2-methylbenzoyl)amino]-4-phenylbutanoyl}-5,5-dimethyl-1,3-thiazolidine-4-carboxamide with HIV enzyme inhibitor | DNPEP, ANPEP, AADAC | LMNA 3400/4885SMN1; SMN2 3215/4885ALDH1A1 526/4885 |
| US-10899788-B2 | Cyclic phosphate substituted nucleoside compounds and methods of use thereof for the treatment of viral diseases | PNP, TYMP, NUDT1 | LMNA 2461/4885SMN1; SMN2 2312/4885ALDH1A1 1886/4885 |
| US-20130164259-A1 | 1,4-SUBSTITUTED PIPERAZINE DERIVATIVES AND METHODS OF USE THEREOF | ZC3HAV1, BAZ2A, HAVCR2 | LMNA 2722/4885SMN1; SMN2 713/4885ALDH1A1 411/4885 |
| US-20110318305-A1 | SUBSTITUTED PYRIDINE AND PYRIMIDINE DERIVATIVES AND THEIR USE IN TREATING VIRAL INFECTIONS | PNP, XDH, PNPO | LMNA 2623/4885SMN1; SMN2 2306/4885ALDH1A1 1973/4885 |
| US-20150057246-A1 | SILYL-CONTAINING HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES | HAVCR2, HBS1L, HBB | LMNA 708/4885SMN1; SMN2 397/4885ALDH1A1 373/4885 |
| US-20160257697-A1 | THIOPHENE-SUBSTITUTED TETRACYCLIC COMPOUNDS AND METHODS OFUSE THEREOF FOR THE TREATMENT OF VIRAL DISEASES | HAVCR2, TPMT, RPL35 | LMNA 4132/4885SMN1; SMN2 2548/4885ALDH1A1 301/4885 |
| US-20140128339-A1 | 2'-METHYL SUBSTITUTED NUCLEOSIDE DERIVATIVES AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES | NSUN2, NT5C3B, MTAP | LMNA 1710/4885SMN1; SMN2 226/4885ALDH1A1 527/4885 |
| US-20160355528-A1 | INHIBITORS OF HIV REPLICATION | RTF2, POLRMT, MAVS | LMNA 3814/4885SMN1; SMN2 4296/4885ALDH1A1 4304/4885 |
| US-20100172866-A1 | Combination Therapy for the Treatment of HCV Infection | SERPINB1, ENPEP, PREP | LMNA 4249/4885SMN1; SMN2 4676/4885ALDH1A1 1005/4885 |
| US-20160243128-A1 | POLYCYCLIC HETEROCYCLE DERIVATIVES AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES | HAVCR2, ZC3HAV1, HCCS | LMNA 2118/4885SMN1; SMN2 3033/4885ALDH1A1 657/4885 |
| US-20070099915-A1 | INHIBITORS OF THE HIV INTEGRASE ENZYME | IMPDH1, INTS9, TYMP | LMNA 3259/4885SMN1; SMN2 4080/4885ALDH1A1 437/4885 |
| US-20110184028-A1 | DERIVATIVES OF PYRIDOXINE FOR INHIBITING HIV INTEGRASE | PNPO, IMPDH1, DPYD | LMNA 1522/4885SMN1; SMN2 3521/4885ALDH1A1 526/4885 |
| US-20070066664-A1 | HIV PROTEASE INHIBITORS, COMPOSITIONS CONTAINING THE SAME, THEIR PHARMACEUTICAL USES, MATERIALS FOR THEIR SYNTHESIS | SERPINB1, PEPD, PREP | LMNA 1767/4885SMN1; SMN2 3937/4885ALDH1A1 2479/4885 |
| US-20150087609-A1 | CYTOTOXIC-DRUG DELIVERING MOLECULES TARGETING HIV (CDM-HS), CYTOTOXIC ACTIVITY AGAINST THE HUMAN IMMUNODEFICIENCY VIRUS AND METHODS OF USE | CD4, HAVCR2, CD74 | LMNA 3978/4885SMN1; SMN2 3989/4885ALDH1A1 3922/4885 |
| US-20070287664-A1 | Combinations of HCV protease inhibitor(s) and CYP3A4 inhibitor(s), and methods of treatment related thereto | CYP3A43, CYP3A4, CYP3A7 | LMNA 3538/4885SMN1; SMN2 4766/4885ALDH1A1 653/4885 |
| US-10703743-B2 | Bifunctional molecules with antibody-recruiting and entry inhibitory activity against the human immunodeficiency virus | CD4, HAVCR2, CD2 | LMNA 3704/4885SMN1; SMN2 3643/4885ALDH1A1 4283/4885 |
| US-20110286965-A1 | ETHENYL-SUBSTITUTED PYRIDINE AND PYRIMIDINE DERIVATIVES AND THEIR USE IN TREATING VIRAL INFECTIONS | CYP2C9, PNP, UGT1A3 | LMNA 2655/4885SMN1; SMN2 2361/4885ALDH1A1 1326/4885 |
| US-10646494-B2 | Heterocycle-substituted tetracyclic compounds and methods of use thereof for the treatment of viral diseases | HAVCR2, HCCS, ZC3HAV1 | LMNA 3229/4885SMN1; SMN2 2259/4885ALDH1A1 202/4885 |
| US-20140199264-A1 | TETRACYCLIC XANTHENE DERIVATIVES AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES | XDH, F12, RXRA | LMNA 592/4885SMN1; SMN2 998/4885ALDH1A1 2108/4885 |
| US-20160311834-A1 | PSEUDOPOLYMORPHS OF AN HCV NS5A INHIBITOR AND USES THEREOF | POLI, HAVCR2, EIF2AK2 | LMNA 3760/4885SMN1; SMN2 4461/4885ALDH1A1 3472/4885 |
| US-20120136023-A1 | Inhibitors of HIV Replication | RTF2, POLRMT, MAVS | LMNA 3814/4885SMN1; SMN2 4296/4885ALDH1A1 4304/4885 |
| US-20060287248-A1 | Asymmetric dosing methods | CTSV, CTSE, PREP | LMNA 1820/4885SMN1; SMN2 4013/4885ALDH1A1 1285/4885 |
| US-20160045526-A1 | 2'-DISUBSTITUTED NUCLEOSIDE DERIVATIVES AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES | SLC28A2, SLC28A1, SLC29A2 | LMNA 2309/4885SMN1; SMN2 622/4885ALDH1A1 1162/4885 |
| US-20060276406-A1 | Methods of treating hepatitis C virus | CTSV, CTSF, CTSE | LMNA 729/4885SMN1; SMN2 3520/4885ALDH1A1 1677/4885 |
| US-20200179428-A1 | CYCLIC PHOSPHATE SUBSTITUTED NUCLEOSIDE DERIVATIVES AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES | PNP, TYMP, ENTPD5 | LMNA 2555/4885SMN1; SMN2 2739/4885ALDH1A1 1844/4885 |
| US-20100092427-A1 | Pyridinone Diketo Acids: Inhibitors of HIV Replication in Combination Therapy | TKT, DHFR, DTYMK | LMNA 3285/4885SMN1; SMN2 4569/4885ALDH1A1 1645/4885 |
| US-20090170846-A1 | INHIBITORS OF THE HIV INTEGRASE ENZYME | IMPDH1, IMPA1, TYMP | LMNA 3075/4885SMN1; SMN2 3999/4885ALDH1A1 406/4885 |
| US-20120282218-A1 | PYRIDINONE HYDROXYCYCLOPENTYL CARBOXAMIDES: HIV INTEGRASE INHIBITORS WITH THERAPEUTIC APPLICATIONS | PAICS, DUT, AADAC | LMNA 3895/4885SMN1; SMN2 4459/4885ALDH1A1 2717/4885 |
| US-20190002447-A1 | BIFUNCTIONAL MOLECULES WITH ANTIBODY-RECRUITING AND ENTRY INHIBITORY ACTIVITY AGAINST THE HUMAN IMMUNODEFICIENCY VIRUS | CD4, HAVCR2, CD2 | LMNA 3704/4885SMN1; SMN2 3643/4885ALDH1A1 4283/4885 |
| US-20070232527-A1 | Medicaments and methods combining a HCV protease inhibitor and an AKR competitor | CTSV, AKR1B1, AKR1A1 | LMNA 3360/4885SMN1; SMN2 4493/4885ALDH1A1 279/4885 |
| US-20060122211-A1 | HIV integrase inhibitors, pharmaceutical compositions and methods for their use | POLB, POLA1, TYMP | LMNA 803/4885SMN1; SMN2 3722/4885ALDH1A1 668/4885 |
| US-20110104110-A1 | SUBSTITUTED INDOLE DERIVATIVES AND METHODS OF USE THEREOF | IDO1, IDO2, INMT | LMNA 3284/4885SMN1; SMN2 2490/4885ALDH1A1 800/4885 |
| US-20140154211-A1 | 2'-SUBSTITUTED NUCLEOSIDE DERIVATIVES AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES | SLC29A2, SLC29A1, SLC28A2 | LMNA 1281/4885SMN1; SMN2 395/4885ALDH1A1 453/4885 |
| US-20200392121-A1 | BIFUNCTIONAL MOLECULES WITH ANTIBODY-RECRUITING AND ENTRY INHIBITORY ACTIVITY AGAINST THE HUMAN IMMUNODEFICIENCY VIRUS | CD4, HAVCR2, CD2 | LMNA 3704/4885SMN1; SMN2 3643/4885ALDH1A1 4283/4885 |
| US-20060281688-A1 | Administration of HCV protease inhibitors in combination with food to improve bioavailability | SERPINB1, HPN, PREP | LMNA 2214/4885SMN1; SMN2 2051/4885ALDH1A1 1626/4885 |
| US-20100098661-A1 | 4,5-RING ANNULATED INDOLE DERIVATIVES FOR TREATING OR PREVENTING OF HCV AND RELATED VIRAL INFECTIONS | ZC3HAV1, IDO1, ZC3HAV1L | LMNA 4667/4885SMN1; SMN2 4714/4885ALDH1A1 248/4885 |
| US-20130156731-A1 | FUSED TRICYCLIC COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEAS | HAVCR2, ELOC, ZC3HAV1 | LMNA 1245/4885SMN1; SMN2 1324/4885ALDH1A1 578/4885 |
| US-20040171842-A1 | HIV protease inhibitors, compositions containing the same, their pharmaceutical uses, material for their synthesis | SERPINB1, PEPD, PREP | LMNA 1628/4885SMN1; SMN2 3736/4885ALDH1A1 2184/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.